

Twelve-month observational study of children with cancer in 41 countries during the COVID-19 pandemic

Global Health Research Group on Children's Non-Communicable Diseases Collaborative

To cite: Global Health Research Group on Children's Non-Communicable Diseases Collaborative. Twelve-month observational study of children with cancer in 41 countries during the COVID-19 pandemic. *BMJ Global Health* 2022;**7**:e008797. doi:10.1136/bmjgh-2022-008797

Handling editor Seye Abimbola

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/bmjgh-2022-008797>).

Received 11 February 2022
Accepted 13 April 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Medical Sciences Division, University of Oxford, Oxford, UK

Correspondence to
Global Health Research Group on Children's Non-Communicable Diseases Collaborative;
bandyopadhyaysoham@gmail.com

ABSTRACT

Introduction Childhood cancer is a leading cause of death. It is unclear whether the COVID-19 pandemic has impacted childhood cancer mortality. In this study, we aimed to establish all-cause mortality rates for childhood cancers during the COVID-19 pandemic and determine the factors associated with mortality.

Methods Prospective cohort study in 109 institutions in 41 countries. Inclusion criteria: children <18 years who were newly diagnosed with or undergoing active treatment for acute lymphoblastic leukaemia, non-Hodgkin's lymphoma, Hodgkin lymphoma, retinoblastoma, Wilms tumour, glioma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, medulloblastoma and neuroblastoma. Of 2327 cases, 2118 patients were included in the study. The primary outcome measure was all-cause mortality at 30 days, 90 days and 12 months.

Results All-cause mortality was 3.4% (n=71/2084) at 30-day follow-up, 5.7% (n=113/1969) at 90-day follow-up and 13.0% (n=206/1581) at 12-month follow-up. The median time from diagnosis to multidisciplinary team (MDT) plan was longest in low-income countries (7 days, IQR 3–11). Multivariable analysis revealed several factors associated with 12-month mortality, including low-income (OR 6.99 (95% CI 2.49 to 19.68); p<0.001), lower middle income (OR 3.32 (95% CI 1.96 to 5.61); p<0.001) and upper middle income (OR 3.49 (95% CI 2.02 to 6.03); p<0.001) country status and chemotherapy (OR 0.55 (95% CI 0.36 to 0.86); p=0.008) and immunotherapy (OR 0.27 (95% CI 0.08 to 0.91); p=0.035) within 30 days from MDT plan. Multivariable analysis revealed laboratory-confirmed SARS-CoV-2 infection (OR 5.33 (95% CI 1.19 to 23.84); p=0.029) was associated with 30-day mortality.

Conclusions Children with cancer are more likely to die within 30 days if infected with SARS-CoV-2. However, timely treatment reduced odds of death. This report provides crucial information to balance the benefits of providing anticancer therapy against the risks of SARS-CoV-2 infection in children with cancer.

INTRODUCTION

In the 1960s, 5-year survival for childhood cancer globally was as low as 20%.¹

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Cancer is the leading cause of death by disease in children. Preliminary data, mostly in high-income countries, suggested that children with cancer and SARS-CoV-2 infection were not at increased risk of death compared with the general paediatric population.

WHAT THIS STUDY ADDS

⇒ This is the largest international cohort study to date to report COVID-19 and oncological outcomes for childhood cancers; the majority of participants were from lower income countries: a neglected group in existing studies. SARS-CoV-2 infection increased odds of death by 30 days, but not after 30 days. Participants in lower income countries had more overall complications, higher odds of starting palliative care and higher odds of death at all time points.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ Given the longer term consequences of delaying treatment, it would be prudent to prioritise timely therapy where feasible. Reducing treatment delays has health and economic benefits and could save countless lives during the pandemic.

The introduction of chemotherapy tripled 5-year survival for childhood cancer in high-income countries (HICs).² Further advances in chemotherapy, radiotherapy, immunotherapy and surgery and the personalisation of treatment increased 5-year survival for childhood cancer in HICs to 80%.^{3–5} Despite this, cancer remains the leading cause of death by disease in children in HICs.⁶ The situation is bleaker in low and middle-income countries (LMICs). The 5-year survival for childhood cancer in LMICs collectively lies between 20% and 30%.^{5,7,8} Even when considering LMICs with the highest 5-year survival for childhood cancer, survival is higher in HICs.^{7,8} Absence of or inaccessibility to both effective diagnostics^{9–11} and optimal care^{12–15}

account for this inequity in childhood cancer outcomes and derive primarily from inadequate healthcare infrastructure and service delivery networks.^{16–18} In recognition of this, the WHO launched the Global Initiative for Childhood Cancer (GICC) in 2018.¹⁹ The GICC laid out a framework for all countries to reach at least 60% 5-year survival for children with the six most common childhood cancers globally by 2030: acute lymphoblastic leukaemia (ALL), Burkitt lymphoma, Hodgkin lymphoma, retinoblastoma, Wilms tumour and low-grade glioma.¹⁹

The year after the launch of the GICC, the SARS-CoV-2 responsible for the COVID-19 pandemic was detected.^{20 21} Preliminary data from HICs suggested that children with cancer and SARS-CoV-2 infection were not at increased risk of mortality compared with the general paediatric population.²² However, children from HICs are not representative of the majority of childhood cancers. More than 90% of children at risk of developing childhood cancer each year live in LMICs,²³ and they account for 95% of the mortality from cancer in this age group worldwide.^{3 16} In the only global cohort study published to date including children with cancer and SARS-CoV-2 infection, the authors detected increased mortality and morbidity in children residing in LMICs.²⁴ However, it was unclear whether this increase in morbidity and mortality was related to infection status or changes in the standard of oncological care provided. Several cross-sectional studies have identified that the COVID-19 pandemic has substantially affected childhood cancer diagnosis and management worldwide, with its effect being more prominent in LMICs than HICs.^{25 26}

In order to support frontline clinicians and governments in making data-driven decisions about the management of childhood cancers, it is critical to determine whether the increased morbidity and mortality documented in the recent cohort study²⁴ are due to SARS-CoV-2 infection or changes from normal standards of care. One of the challenges of paediatric cancer research is that it is a relatively small disease population.² To overcome this obstacle, multicentre studies are essential to generate statistically significant results. Given global studies published to date on childhood cancers during the COVID-19 pandemic have predominantly collected data from HICs, it is also critical to increase data collection from LMICs. However, given the extra pressures on clinicians currently—especially in LMICs—it is also imperative to reduce data collection burden by focussing on a subset of cancers; principally, those espoused by GICC. This study primarily aims to determine all-cause mortality rates for childhood cancers during the COVID-19 pandemic across LMICs and HICs. The secondary aim of the study is to determine the factors that influenced these outcomes including tumour-specific data, patient-specific demographics and changes to health system frameworks as outlined in the study protocol.²⁷

METHODS

Study design and participants

This is a prospective cohort study with cases reported from 109 institutions in 41 countries (online supplemental appendix S2). Data was collected in the REDCap application hosted at the University of Oxford (Oxford, UK). Data were voluntarily reported for all children under the age of 18 years who were newly diagnosed with or undergoing active treatment for an eligible cancer between 12 March 2020—the date that the WHO declared the start of the COVID-19 pandemic—and 12 December 2020 inclusive. Eligible cancers were those identified by the GICC¹⁹ and those deemed significant by LMIC collaborators: ALL, non-Hodgkin's lymphoma (including Burkitt lymphoma), Hodgkin lymphoma, retinoblastoma, Wilms tumour, glioma, sarcoma (osteosarcoma, Ewing sarcoma and rhabdomyosarcoma), medulloblastoma and neuroblastoma.²⁸ Participants who were 18 years or older were excluded to reduce confounding by care provided by adult cancer services. There were no centre-specific exclusion criteria. This study was reviewed by the University of Oxford institutional review board as not involving human participants, and no identifiable private information or biospecimens being provided. This study was subjected to approvals by local ethics committees according to local policy. Individual investigators (listed in online supplemental appendix S1) were responsible for assuring that participation was compliant with local regulations.

Procedures

Deidentified data were requested on a maximum of 112 variables (10 required responses) contained on eight forms. Baseline information was collected regarding the patient's age, weight, sex, American Society of Anaesthesiologists (ASA) grade and whether the patient was newly diagnosed with or undergoing active treatment for an eligible cancer between 12 March 2020 and 12 December 2020 inclusive. Participants 18 years or older and participant data outside of this data range were excluded. Where date of birth was unknown, the contributor of that data set was contacted to verify the patient was born in 2003 or later. Tumour-specific data were collected regarding diagnosis,²⁸ date of diagnosis, staging,²⁹ multidisciplinary team (MDT) decision date, what the MDT management plan was during the pandemic, and what the MDT plan would have been prior to the pandemic. The time from diagnosis to MDT decision date was calculated for each patient. Data were collected regarding the chemotherapy, radiotherapy, immunotherapy, surgery, and palliative care that patients received, any deviations from the MDT plan made during the pandemic, and any specific factors related to the COVID-19 pandemic that had driven these deviations. Outcomes collected included laboratory and clinical status of SARS-CoV-2 infection, complications within 30 days from anticancer treatment, interruptions in cancer-directed treatment and vital status. All terminology used were selected to be globally applicable and clinically relevant. Participant data could be collected




Figure 1 STROBE flowchart of participants in this study. STROBE, STrengthening the Reporting of OBServational studies in Epidemiology.

prospectively or retrospectively provided 30-day, 90-day and 12-month follow-up data were collected prospectively. Each institution that had reported at least a single case was requested to confirm that all institutional cases had been entered in an unbiased fashion as of the time of the final case entry by the institution. All cases corresponding to institutions that did not confirm unbiased data entry were excluded from analysis. Data validation was performed on a randomly selected subset (10%) of participating centres. A research checklist has been used to report the study (online supplemental appendix S3).

Statistical analysis

Descriptive statistics were used to summarise demographic and clinical characteristics and outcomes. 2021 World Bank designations for income groups—HICs, upper middle-income countries (UMICs), lower middle-income countries (LoMICs) and low-income countries (LICs)—were used to describe economic context.³⁰ The primary outcome measures were all-cause mortality at 30 days, 90 days and 12 months from MDT plan. Secondary outcomes were treatment modification, complications within 30 days of first anticancer treatment and SARS-CoV-2 infection status: cases were those confirmed by laboratory testing; cases without laboratory confirmation were classified as ‘probably SARS-CoV-2’. Another secondary outcome was the health system framework factors affected by the COVID-19 pandemic, defined as one or more of the following: decision-making, infrastructure, workforce, service delivery, financing and patient factors. Comparison of proportions between groups was made with χ^2 . The Kruskal-Wallis test and Dunn’s post hoc test were used to compare medians between groups. Univariate logistic regression was used to examine the association between each outcome and patient characteristics. Multivariable logistic regression

was used to explore the effect of factors that were significant ($p < 0.05$) in univariate analyses for each outcome. All data analyses were done using STATA/IC V.16.1.

Role of the funding source

The funders of the study had no role in the study design, data collection, data analysis, data interpretation or writing of the report.

RESULTS

Between 12 March 2020 and 12 December 2020, 2327 cases were identified. Of these 2327 cases, 209 were excluded from analyses (figure 1). Thirty-eight were duplicates of cases that had already been included into the study, 14 were 18 years or older and 157 were excluded based on cancer diagnosis eligibility. Of the remaining 2118 qualifying cases, 2084 (98.4%) completed 30-day follow-up, 1969 (93.0%) completed 90-day follow-up and 1581 (74.6%) completed 12-month follow-up. Clinical characteristics of the included patients by World Bank country income level are summarised in table 1. Most patients ($n=1450/2118$, 68.5%) were from LMICs, principally LoMICs ($n=766/2118$, 36.2%) (online supplemental appendix S4). The median age of patients included was 6 years (IQR 3–11), with 7.6% ($n=161/2107$) younger than 1 year and 8.7% ($n=183/2107$) aged 15–17 years, with age missing for 11 patients. 1244 (59.0%) of 2108 patients were men, with sex missing for 10 patients and one participant being inter-sex.

Data were available for 1215 patients who were newly diagnosed with cancer during the COVID-19 pandemic concerning the time from diagnosis to the time the initial MDT management plan was made. The median time from diagnosis to MDT plan varied across LICs (7 days, IQR 3–11; $n=23$), LoMICs (2 days, IQR 0–8; $n=524$), UMICs (1 day, IQR 0–9; $n=348$) and HICs (2 days, IQR 0–7; $n=320$). The Kruskal-Wallis test revealed a statistically significant difference in median time from diagnosis to MDT plan ($\chi^2=10.688$, $p=0.0135$) between two or more of the income groups. Pairwise comparisons using Dunn’s test indicated that the median time from diagnosis to MDT plan among LIC patients was significantly different from those of LoMIC ($p=0.009$), UMIC ($p=0.002$) and HIC ($p=0.003$) patients. Dunn’s test also indicated that the median time from diagnosis to MDT plan among LoMIC patients was significantly different from those of UMIC ($p=0.030$) patients. No other differences were statistically significant at a significance level of 0.05.

The MDT plans made for all the participants are summarised in table 2. MDTs in HICs were observed to be significantly more likely to opt for chemotherapy ($\chi^2=7.462$, $p=0.006$) and immunotherapy ($\chi^2=32.019$, $p < 0.001$) over no treatment compared with MDTs in LMICs. No other differences between HICs and LMICs were statistically significant at a significance level of 0.05. Among patients planned for chemotherapy

Table 1 Baseline characteristics by World Bank income group

| | Low-income countries (N=36), n (%) | Lower-middle income countries (N=766), n (%) | Upper-middle income countries (N=648), n (%) | High-income countries (N=668), n (%) |
|--|---------------------------------------|--|--|---|
| Age (years), median (IQR) | 4 (2.5, 7), 36 (100) | 5 (3, 10), 761 (99.3) | 6 (2, 11), 647 (99.8) | 7 (3, 12), 663 (99.3) |
| Sex | | | | |
| Female | 15 (41.7) | 277 (36.2) | 296 (45.7) | 275 (41.2) |
| Male | 21 (58.3) | 485 (63.3) | 351 (54.2) | 387 (57.9) |
| Intersex | 0 (0) | 0 (0) | 0 (0) | 1 (0.1) |
| Missing | 0 (0) | 4 (0.5) | 1 (0.1) | 5 (0.7) |
| Weight (kg), median (range) | 17.7 (15.0, 27.75), 36 (100) | 17.7 (12.0, 26.0), 741 (96.7) | 20.3 (14.1, 35), 632 (97.5) | 25 (16, 46.4), 648 (97.0) |
| American Society of Anesthesiologists (ASA) grade | | | | |
| 1—A normal healthy patient | 2 (5.6) | 198 (25.8) | 169 (26.1) | 107 (16.0) |
| 2—A patient with mild systemic disease | 21 (58.3) | 218 (28.5) | 377 (58.2) | 259 (38.8) |
| 3—A patient with severe systemic disease | 8 (22.2) | 132 (17.2) | 90 (13.9) | 267 (40.0) |
| 4—A patient with severe systemic disease that is a constant threat to life | 3 (8.3) | 39 (5.1) | 9 (1.4) | 25 (3.7) |
| 5—A moribund patient who is not expected to survive without an operation | 2 (5.6) | 6 (0.8) | 2 (0.3) | 1 (0.1) |
| Missing | 0 (0) | 173 (22.6) | 1 (0.2) | 9 (1.3) |
| Tumour type | | | | |
| Acute lymphoblastic leukaemia | 11 (30.6) | 292 (38.1) | 251 (38.7) | 291 (43.6) |
| Ewing sarcoma | 0 (0) | 30 (3.9) | 21 (3.2) | 33 (4.9) |
| Glioma | 1 (2.8) | 30 (3.9) | 57 (8.8) | 79 (11.8) |
| Hodgkin lymphoma | 3 (8.3) | 48 (6.3) | 30 (4.6) | 43 (6.4) |
| Medulloblastoma | 4 (11.1) | 29 (3.8) | 47 (7.3) | 33 (4.9) |
| Neuroblastoma | 4 (11.1) | 48 (6.3) | 45 (6.9) | 61 (9.1) |
| Non-Hodgkin lymphoma | 4 (11.1) | 53 (6.9) | 45 (6.9) | 36 (5.4) |
| Osteosarcoma | 0 (0.0) | 24 (3.1) | 37 (5.7) | 28 (4.2) |
| Retinoblastoma | 6 (16.7) | 47 (6.1) | 40 (6.2) | 6 (0.9) |
| Rhabdomyosarcoma | 1 (2.8) | 47 (6.1) | 25 (3.9) | 30 (4.5) |
| Wilms tumour | 2 (5.6) | 118 (15.4) | 50 (7.7) | 28 (4.2) |

by the MDT, there was a significant difference between the proportion of patients who had a central venous catheter inserted in two or more of the income groups ($\chi^2=479.287$, $p<0.001$): 84.0% ($n=489/582$) in HICs, 61.1% ($n=275/450$) in UMICs, 24.9% ($n=163/654$) in LoMICs and 0.0% ($n=0/31$) in LICs. Of the 2118 participants, 20 (0.9%) would reportedly have had a different management plan if the MDT meeting had been held prior to the pandemic: 17 (85.0%) were based in LoMICs and 3 (15.0%) in UMICs.

There was a significant difference in laboratory testing for SARS-CoV-2 infection ($\chi^2=213.606$, $p<0.001$) between HICs ($n=362/635$, 57.0%) and LMICs ($n=318/1347$, 23.6%). In LMICs, most patients were not screened for SARS-CoV-2 infection ($n=719/1347$, 53.4%). A minority of participants in LMICs underwent symptomatic screening ($n=300/1347$, 22.3%) or CT testing ($n=10/1347$, 0.7%). In HICs, 192 patients (30.2%) were

not screened for SARS-CoV-2 infection. The remaining 81 patients in HICs (12.8%) underwent symptomatic screening only. Thirty-five patients were confirmed to be infected with SARS-CoV-2 following laboratory testing (HICs: 7; LMICs: 28), and 27 patients were suspected to probably have SARS-CoV-2 infection (HICs: 2; LMICs: 25).

A total of 212 patients (10.0%), 42 patients (2.0%), 5 patients (0.2%) and 98 patients (4.6%) were, respectively, reported to have had their chemotherapy, radiotherapy, immunotherapy and surgery care affected by the COVID-19 pandemic. In multivariable analysis, residing in an LMIC (OR 3.72 (95% CI 2.52 to 5.50)) was associated with increased odds of oncological care being affected by the COVID-19 pandemic. Online supplemental appendix S5 summarises the specific factors related to the COVID-19 pandemic that were reported to have affected cancer care. Of 2075 patients, 238 patients

Table 2 Treatments planned and received during the COVID-19 pandemic by World Bank income group

| | Low-income countries % (n/N) | Lower-middle income countries % (n/N) | Upper-middle income countries % (n/N) | High-income countries % (n/N) |
|--|---------------------------------|--|--|----------------------------------|
| Multi-disciplinary team (MDT) management plan during the pandemic | | | | |
| Chemotherapy | 86.1 (31/36) | 89.4 (685/766) | 84.0 (544/648) | 91.0 (608/668) |
| Radiotherapy | 16.7 (6/36) | 16.7 (128/766) | 12.7 (82/648) | 16.8 (112/668) |
| Immunotherapy | 0.0 (0/36) | 0.3 (2/766) | 2.9 (19/648) | 5.8 (39/668) |
| Surgery | 30.6 (11/36) | 31.9 (244/766) | 33.0 (214/648) | 28.6 (191/668) |
| Palliative care | 8.3 (3/36) | 0.8 (6/766) | 0.5 (3/648) | 0.6 (4/668) |
| MDT plan that would have been proposed prior to the pandemic | | | | |
| Chemotherapy | 86.1 (31/36) | 90.2 (691/766) | 83.8 (543/648) | 91.0 (608/668) |
| Radiotherapy | 16.7 (6/36) | 17.1 (131/766) | 12.8 (83/648) | 16.8 (112/668) |
| Immunotherapy | 0.0 (0/36) | 0.5 (4/766) | 2.9 (19/648) | 5.8 (39/668) |
| Surgery | 30.6 (11/36) | 31.1 (238/766) | 32.9 (213/648) | 28.6 (191/668) |
| Palliative care | 8.3 (3/36) | 0.5 (4/766) | 0.5 (3/648) | 0.6 (4/668) |
| Treatment provided within 30 days for patients planned to have that treatment at MDT | | | | |
| Chemotherapy | 80.6 (25/31) | 84.7 (559/660) | 86.4 (389/450) | 87.8 (496/565) |
| Radiotherapy | 0.0 (0/6) | 22.0 (28/127) | 44.4 (20/45) | 42.2 (43/102) |
| Immunotherapy | – | 100.0 (2/2) | 75.0 (12/16) | 55.9 (19/34) |
| Surgery | 18.2 (2/11) | 27.6 (62/225) | 36.4 (60/165) | 36.4 (63/173) |
| Treatment provided within 90 days for patients planned to have that treatment at MDT | | | | |
| Chemotherapy | 80.6 (25/31) | 88.9 (601/676) | 88.7 (481/542) | 91.3 (553/606) |
| Radiotherapy | 0.0 (0/6) | 48.0 (60/125) | 39.0 (32/82) | 46.8 (52/111) |
| Immunotherapy | – | 100.0 (2/2) | 89.5 (17/19) | 69.2 (27/39) |
| Surgery | 18.2 (2/11) | 84.0 (110/131) | 38.8 (83/214) | 47.1 (89/189) |
| Treatment provided within 12 months for patients planned to have that treatment at MDT | | | | |
| Chemotherapy | 90.0 (27/30) | 96.6 (625/647) | 95.1 (504/530) | 93.7 (562/600) |
| Radiotherapy | 0.0 (0/6) | 62.7 (69/110) | 49.4 (40/81) | 54.7 (58/106) |
| Immunotherapy | – | 100.0 (2/2) | 89.5 (17/19) | 83.3 (30/36) |
| Surgery | 45.5 (5/11) | 75.7 (159/210) | 66.0 (132/200) | 64.0 (119/186) |
| Treatment provided within 12 months for all patients | | | | |
| Chemotherapy | 84.9 (28/33) | 92.5 (649/702) | 88.9 (552/621) | 88.4 (577/653) |
| Radiotherapy | 0.0 (0/30) | 16.6 (93/560) | 20.8 (119/571) | 12.7 (76/599) |
| Immunotherapy | 0.0 (0/30) | 1.5 (8/547) | 9.8 (54/551) | 10.7 (64/597) |
| Surgery | 22.6 (7/31) | 37.2 (226/607) | 34.6 (202/584) | 33.7 (207/615) |

(11.5%) were started on palliative care. 232 of these patients originally had treatment plans made at the initial MDT: 206 (14.6%) of 1413 participants in LMICs and 26 (3.9%) of 662 participants in HICs ($\chi^2=51.502$, $p<0.001$) (online supplemental appendix S6). Income group, age, sex, ASA grade, chemotherapy and radiotherapy within 30 days of the MDT, change in radiotherapy and surgery treatment due to the COVID-19 pandemic and tumour type were significantly associated with palliative treatment in univariate logistic regression analyses, whereas immunotherapy within 30 days of the MDT, surgery within 30 days of the MDT and SARS-CoV-2 infection status were not. In multivariable analysis, residing in an LIC (OR

27.13 (95% CI 12.7 to 58.6); $p<0.001$), an LoMIC (OR 3.29 (95% CI 2.10 to 5.17); $p<0.001$), and an UMIC (OR 4.82 (95% CI 3.09 to 7.51); $p<0.001$) were associated with increased odds of palliative care. Increasing age, male sex, ASA grade, radiotherapy within 30 days of the MDT and tumour type were also associated with increased odds of palliative care (table 3).

At 30 days, there were 71 (3.4%) deaths in this cohort with 66 deaths (4.6%) among 1427 participants in LMICs, and five deaths (0.8%) among 657 participants in HICs ($\chi^2=20.411$, $p<0.001$). Income group, ASA grade, chemotherapy within 30 days of the MDT, SARS-CoV-2 infection status and tumour type were significantly associated with

Table 3 Results of univariate and multivariable analysis for palliative care

| | Univariate analysis | | Multivariable analysis (N=1706) | |
|--|---------------------|----------------------|---------------------------------|-------------------------|
| | P value | Odds ratio (95% CI) | P value | Odds ratio (95% CI) |
| Income group | | | | |
| High-income countries | Reference | 1.0 | Reference | 1.0 |
| Upper-middle income countries | <0.001 | 4.82 (3.09 to 7.51) | <0.001 | 7.52 (4.45 to 12.69) |
| Lower-middle income countries | <0.001 | 3.29 (2.10 to 5.17) | <0.001 | 5.09 (3.03 to 8.56) |
| Low-income countries | <0.001 | 27.3 (12.7 to 58.6) | <0.001 | 44.46 (19.15 to 103.23) |
| Age (for every year older) | 0.004 | 1.04 (1.01 to 1.07) | 0.001 | 1.06 (1.02 to 1.10) |
| Sex | | | | |
| Female | Reference | 1.0 | Reference | 1.0 |
| Male | 0.046 | 1.34 (1.01 to 1.77) | 0.026 | 1.45 (1.04 to 2.00) |
| American Society of Anaesthesiologists (ASA) grade | | | | |
| 1 | Reference | 1.0 | Reference | 1.0 |
| 2 | 0.005 | 1.73 (1.18 to 2.55) | 0.001 | 2.09 (1.34 to 3.26) |
| 3 | 0.307 | 1.26 (0.81 to 1.96) | 0.001 | 2.54 (1.48 to 4.36) |
| 4 | <0.001 | 4.27 (2.34 to 7.80) | <0.001 | 4.95 (2.43 to 10.09) |
| 5 | <0.001 | 9.32 (2.72 to 31.96) | 0.011 | 5.99 (1.50 to 23.99) |
| Treatment provided within 30 days | | | | |
| Chemotherapy | <0.001 | 0.43 (0.31 to 0.57) | 0.119 | 0.74 (0.51 to 1.08) |
| Radiotherapy | <0.001 | 2.87 (1.93 to 4.28) | 0.013 | 1.83 (1.14 to 2.96) |
| Immunotherapy | 0.083 | 0.45 (0.18 to 1.11) | NA | NA |
| Surgery | 0.683 | 1.09 (0.73 to 1.61) | NA | NA |
| Changes to treatment due to the COVID-19 pandemic | | | | |
| Change to chemotherapy | 0.123 | 1.38 (0.92 to 2.07) | NA | NA |
| Change to radiotherapy | 0.038 | 2.22 (1.04 to 4.70) | 0.808 | 0.90 (0.37 to 2.17) |
| Change to immunotherapy | NA | NA | NA | NA |
| Change to surgery | 0.009 | 2.01 (1.19 to 3.39) | 0.092 | 1.82 (0.91 to 3.66) |
| Tumour type | | | | |
| Acute lymphoblastic leukaemia | Reference | 1.0 | Reference | 1.0 |
| Ewing sarcoma | 0.473 | 1.35 (0.59 to 3.07) | 0.559 | 1.31 (0.53 to 3.19) |
| Glioma | <0.001 | 3.97 (2.55 to 6.20) | <0.001 | 4.28 (2.40 to 7.62) |
| Hodgkin lymphoma | 0.839 | 0.92 (0.43 to 1.98) | 0.435 | 0.70 (0.29 to 1.70) |
| Medulloblastoma | <0.001 | 4.42 (2.67 to 7.30) | 0.002 | 2.59 (1.40 to 4.79) |
| Neuroblastoma | 0.010 | 2.00 (1.18 to 3.39) | 0.013 | 2.22 (1.18 to 4.17) |
| Non-Hodgkin lymphoma | 0.482 | 1.26 (0.66 to 2.41) | 0.910 | 0.96 (0.46 to 2.00) |
| Osteosarcoma | <0.001 | 3.47 (1.94 to 6.22) | 0.008 | 2.57 (1.28 to 5.13) |
| Retinoblastoma | 0.474 | 1.31 (0.63 to 2.73) | 0.933 | 0.96 (0.41 to 2.26) |
| Rhabdomyosarcoma | <0.001 | 2.77 (1.56 to 4.91) | 0.002 | 2.84 (1.46 to 5.51) |
| Wilms tumour | 0.301 | 1.34 (0.77 to 2.32) | 0.237 | 1.48 (0.77 to 2.85) |
| SARS-CoV-2 infection status | | | | |
| Not suspected or detected | Reference | 1.0 | NA | NA |
| Probable SARS-CoV-2 infection | 0.534 | 1.40 (0.48 to 4.10) | NA | NA |
| Laboratory confirmed SARS-CoV-2 infection | 0.938 | 1.04 (0.36 to 2.98) | NA | NA |

death at 30 days (table 4). No other factors were statistically significant at a significance level of 0.05. Thirty-day complications from the various anticancer therapies are

described in online supplemental appendix S7. At 90 days, there were 113 (5.7%) deaths in this cohort with 105 deaths (7.9%) among 1321 participants in LMICs,

Table 4 Univariate analysis and multivariable analysis of patient vital status at 30 days, 90 days and 12 months

| | Univariate analysis | | Multivariable analysis | |
|--|---------------------|-------------------------|------------------------|------------------------|
| | P value | OR (95% CI) | P value | OR (95% CI) |
| Factors associated with death at 30 days | | | | |
| Income group | | | | |
| High-income countries | Reference | 1.0 | Reference | 1.0 |
| Upper-middle income countries | 0.090 | 2.48 (0.87 to 7.07) | 0.150 | 2.43 (0.72 to 8.15) |
| Lower-middle income countries | <0.001 | 8.36 (3.30 to 21.19) | <0.001 | 9.52 (3.46 to 26.20) |
| Low-income countries | <0.001 | 43.47 (13.64 to 138.52) | <0.001 | 39.79 (9.65 to 164.16) |
| Age (for every year older) | 0.858 | 1.00 (0.95 to 1.05) | NA | NA |
| Sex | | | | |
| Female | Reference | 1.0 | NA | NA |
| Male | 0.961 | 0.99 (0.61 to 1.60) | NA | NA |
| Weight (for every kg heavier) | 0.247 | 0.99 (0.98 to 1.01) | NA | NA |
| American Society of Anaesthesiologists (ASA) grade | | | | |
| 1 | Reference | 1.0 | Reference | 1.0 |
| 2 | 0.722 | 0.87 (0.39 to 1.92) | 0.471 | 0.72 (0.29 to 1.77) |
| 3 | 0.125 | 1.84 (0.84 to 3.99) | 0.077 | 2.27 (0.91 to 5.64) |
| 4 | <0.001 | 13.69 (5.98 to 31.34) | <0.001 | 8.93 (3.34 to 23.85) |
| 5 | <0.001 | 55.08 (14.39 to 210.78) | <0.001 | 30.75 (4.70 to 200.98) |
| Tumour type | | | | |
| Acute lymphoblastic leukaemia | Reference | 1.0 | Reference | 1.0 |
| Ewing sarcoma | 0.708 | 0.68 (0.09 to 5.19) | 0.791 | 1.34 (0.15 to 11.65) |
| Glioma | 0.003 | 3.52 (1.56 to 7.97) | 0.106 | 2.55 (0.82 to 7.92) |
| Hodgkin lymphoma | NA (no deaths) | NA (no deaths) | NA (no deaths) | NA (no deaths) |
| Medulloblastoma | <0.001 | 7.92 (3.71 to 16.90) | 0.001 | 6.33 (2.22 to 18.04) |
| Neuroblastoma | 0.044 | 2.56 (1.03 to 6.39) | 0.560 | 1.43 (0.43 to 4.81) |
| Non-Hodgkin lymphoma | 0.001 | 3.95 (1.69 to 9.22) | 0.047 | 3.12 (1.01 to 9.62) |
| Osteosarcoma | 0.657 | 0.63 (0.08 to 4.83) | 0.703 | 1.51 (0.18 to 12.80) |
| Retinoblastoma | 0.040 | 2.95 (1.05 to 8.30) | 0.563 | 1.54 (0.36 to 6.69) |
| Rhabdomyosarcoma | 0.044 | 2.89 (1.03 to 8.12) | 0.069 | 3.01 (0.92 to 9.89) |
| Wilms tumour | 0.764 | 1.19 (0.39 to 3.62) | 0.807 | 0.85 (0.24 to 3.07) |
| Treatment provided within 30 days | | | | |
| Chemotherapy | <0.001 | 0.20 (0.12 to 0.32) | 0.002 | 0.35 (0.18 to 0.69) |
| Radiotherapy | 0.466 | 1.35 (0.60 to 3.00) | NA | NA |
| Immunotherapy | NA (no deaths) | NA (no deaths) | NA (no deaths) | NA (no deaths) |
| Surgery | 0.644 | 0.84 (0.40 to 1.77) | NA | NA |
| Changes to treatment due to the COVID-19 pandemic | | | | |
| Change to chemotherapy | 0.961 | 0.98 (0.44 to 2.17) | NA | NA |
| Change to radiotherapy | 0.149 | 2.42 (0.73 to 8.06) | NA | NA |
| Change to immunotherapy | NA (no deaths) | NA (no deaths) | NA (no deaths) | NA (no deaths) |
| Change to surgery | 0.278 | 1.68 (0.66 to 4.27) | NA | NA |
| SARS-CoV-2 infection status | | | | |
| Not suspected or detected | Reference | 1.0 | Reference | 1.0 |
| Probable SARS-CoV-2 infection | <0.001 | 7.40 (2.70 to 20.25) | 0.002 | 8.40 (2.23 to 31.58) |
| Laboratory confirmed SARS-CoV-2 infection | 0.071 | 3.05 (0.91 to 10.26) | 0.029 | 5.33 (1.19 to 23.84) |
| Factors associated with death at 90 days | | | | |
| Income group | | | | |
| High-income countries | Reference | 1.0 | Reference | 1.0 |
| Upper-middle income countries | <0.001 | 5.43 (2.52 to 11.70) | <0.001 | 6.12 (2.71 to 13.81) |
| Lower-middle income countries | <0.001 | 7.42 (3.51 to 15.69) | <0.001 | 10.19 (4.52 to 22.97) |

Continued

Table 4 Continued

| | Univariate analysis | | Multivariable analysis | |
|--|---------------------|-------------------------|------------------------|------------------------|
| | P value | OR (95% CI) | P value | OR (95% CI) |
| Low-income countries | <0.001 | 31.30 (11.07 to 88.50) | <0.001 | 23.94 (7.06 to 81.21) |
| Age (for every year older) | 0.870 | 1.00 (0.97 to 1.04) | NA | NA |
| Sex | | | | |
| Female | Reference | 1.0 | Reference | 1.0 |
| Male | 0.595 | 0.90 (0.61 to 1.32) | NA | NA |
| Weight (for every kg heavier) | 0.284 | 0.99 (0.98 to 1.01) | NA | NA |
| American Society of Anaesthesiologists (ASA) grade | | | | |
| 1 | Reference | 1.0 | Reference | 1.0 |
| 2 | 0.013 | 2.34 (1.20 to 4.55) | 0.021 | 2.32 (1.14 to 4.73) |
| 3 | 0.023 | 2.29 (1.12 to 4.67) | 0.002 | 3.36 (1.56 to 7.21) |
| 4 | <0.001 | 12.61 (5.60 to 28.40) | <0.001 | 9.59 (3.78 to 24.32) |
| 5 | <0.001 | 75.64 (16.71 to 342.28) | <0.001 | 29.39 (5.02 to 172.07) |
| Tumour type | | | | |
| Acute lymphoblastic leukaemia | Reference | 1.0 | Reference | 1.0 |
| Ewing sarcoma | 0.580 | 0.66 (0.16 to 2.83) | 0.519 | 1.65 (0.36 to 7.47) |
| Glioma | 0.015 | 2.31 (1.17 to 4.53) | 0.029 | 2.76 (1.11 to 6.86) |
| Hodgkin lymphoma | NA (no deaths) | NA (no deaths) | NA (no deaths) | NA (no deaths) |
| Medulloblastoma | <0.001 | 5.30 (2.84 to 9.89) | <0.001 | 4.30 (1.92 to 9.65) |
| Neuroblastoma | 0.003 | 2.77 (1.43 to 5.36) | 0.002 | 3.37 (1.57 to 7.23) |
| Non-Hodgkin lymphoma | 0.013 | 2.48 (1.21 to 5.08) | 0.091 | 2.11 (0.89 to 5.02) |
| Osteosarcoma | 0.320 | 1.64 (0.62 to 4.34) | 0.042 | 3.04 (1.04 to 8.87) |
| Retinoblastoma | 0.183 | 1.85 (0.75 to 4.57) | 0.988 | 1.01 (0.32 to 3.13) |
| Rhabdomyosarcoma | 0.053 | 2.32 (0.99 to 5.47) | 0.087 | 2.30 (0.89 to 5.95) |
| Wilms tumour | 0.837 | 1.09 (0.47 to 2.53) | 0.911 | 1.05 (0.42 to 2.61) |
| Treatment provided within 90 days | | | | |
| Chemotherapy | <0.001 | 0.26 (0.17 to 0.39) | 0.002 | 0.42 (0.24 to 0.73) |
| Radiotherapy | 0.642 | 0.86 (0.47 to 1.60) | NA | NA |
| Immunotherapy | NA (no deaths) | NA (no deaths) | NA (no deaths) | NA (no deaths) |
| Surgery | 0.015 | 0.48 (0.27 to 0.87) | 0.001 | 0.32 (0.16 to 0.65) |
| Changes to treatment due to the COVID-19 pandemic | | | | |
| Change to chemotherapy | 0.467 | 1.25 (0.69 to 2.27) | NA | NA |
| Change to radiotherapy | 0.026 | 3.02 (1.14 to 7.98) | 0.728 | 1.23 (0.39 to 3.90) |
| Change to immunotherapy | NA (no deaths) | NA (no deaths) | NA (no deaths) | NA (no deaths) |
| Change to surgery | 0.059 | 2.00 (0.97 to 4.10) | NA | NA |
| SARS-CoV-2 infection status | | | | |
| Not suspected or detected | Reference | 1.0 | Reference | 1.0 |
| Probable SARS-CoV-2 infection | 0.002 | 4.95 (1.80 to 13.60) | 0.018 | 3.90 (1.26 to 12.09) |
| Laboratory confirmed SARS-CoV-2 infection | 0.403 | 1.67 (0.50 to 5.55) | 0.467 | 1.64 (0.43 to 6.28) |
| Factors associated with death at 12 months | | | | |
| Income group | | | | |
| High-income countries | Reference | 1.0 | Reference | 1.0 |
| Upper-middle income countries | <0.001 | 2.22 (1.44 to 3.41) | <0.001 | 3.49 (2.02 to 6.03) |
| Lower-middle income countries | <0.001 | 2.78 (1.82 to 4.26) | <0.001 | 3.32 (1.96 to 5.61) |
| Low-income countries | <0.001 | 6.58 (2.86 to 15.15) | <0.001 | 6.99 (2.49 to 19.68) |
| Age (for every year older) | 0.226 | 1.02 (0.99 to 1.05) | NA | NA |
| Sex | | | | |
| Female | Reference | 1.0 | Reference | 1.0 |
| Male | 0.694 | 1.06 (0.79 to 1.43) | NA | NA |

Continued

Table 4 Continued

| | Univariate analysis | | Multivariable analysis | |
|--|---------------------|------------------------|------------------------|------------------------|
| | P value | OR (95% CI) | P value | OR (95% CI) |
| Weight (for every kg heavier) | 0.874 | 1.00 (0.99 to 1.01) | NA | NA |
| American Society of Anaesthesiologists (ASA) grade | | | | |
| 1 | Reference | 1.0 | Reference | 1.0 |
| 2 | 0.632 | 1.11 (0.72 to 1.71) | 0.211 | 1.37 (0.83 to 2.26) |
| 3 | 0.044 | 1.62 (1.01 to 2.59) | <0.001 | 3.24 (1.81 to 5.79) |
| 4 | <0.001 | 5.34 (2.78 to 10.27) | <0.001 | 6.58 (3.03 to 14.26) |
| 5 | <0.001 | 26.72 (5.18 to 137.95) | 0.002 | 17.51 (2.87 to 106.80) |
| Tumour type | | | | |
| Acute lymphoblastic leukaemia | Reference | 1.0 | Reference | 1.0 |
| Ewing sarcoma | 0.106 | 1.93 (0.87 to 4.28) | 0.133 | 2.01 (0.81 to 4.99) |
| Glioma | <0.001 | 3.71 (2.21 to 6.24) | 0.003 | 2.87 (1.45 to 5.70) |
| Hodgkin lymphoma | 0.067 | 0.26 (0.06 to 1.10) | – | – |
| Medulloblastoma | <0.001 | 3.97 (2.30 to 6.86) | 0.040 | 2.12 (1.03 to 4.33) |
| Neuroblastoma | <0.001 | 3.42 (2.04 to 5.73) | <0.001 | 3.26 (1.80 to 5.90) |
| Non-Hodgkin lymphoma | 0.015 | 2.10 (1.16 to 3.83) | 0.224 | 1.58 (0.76 to 3.32) |
| Osteosarcoma | <0.001 | 3.69 (1.94 to 7.02) | <0.001 | 4.54 (2.18 to 9.47) |
| Retinoblastoma | 0.356 | 1.45 (0.66 to 3.17) | 0.724 | 0.84 (0.31 to 2.25) |
| Rhabdomyosarcoma | <0.001 | 3.38 (1.75 to 6.50) | 0.054 | 2.18 (0.99 to 4.80) |
| Wilms tumour | 0.453 | 1.29 (0.67 to 2.48) | 0.942 | 1.03 (0.47 to 2.25) |
| Treatment provided within 30 days | | | | |
| Chemotherapy | <0.001 | 0.36 (0.25 to 0.49) | 0.008 | 0.55 (0.36 to 0.86) |
| Radiotherapy | 0.002 | 2.03 (1.29 to 3.21) | 0.069 | 1.68 (0.96 to 2.94) |
| Immunotherapy | 0.036 | 0.29 (0.09 to 0.92) | 0.035 | 0.27 (0.08 to 0.91) |
| Surgery | 0.589 | 0.88 (0.55 to 1.40) | NA | NA |
| Treatment provided within 90 days | | | | |
| Chemotherapy | <0.001 | 0.32 (0.23 to 0.45) | NA | NA (co-linearity) |
| Radiotherapy | 0.020 | 1.60 (1.08 to 2.37) | NA | NA (co-linearity) |
| Immunotherapy | 0.082 | 0.47 (0.20 to 1.10) | NA | NA |
| Surgery | 0.777 | 0.95 (0.65 to 1.38) | NA | NA |
| Changes to treatment due to the COVID-19 pandemic | | | | |
| Change to chemotherapy | 0.555 | 1.15 (0.72 to 1.86) | NA | NA |
| Change to radiotherapy | 0.001 | 4.08 (1.84 to 9.03) | 0.403 | 1.50 (0.58 to 3.92) |
| Change to immunotherapy | NA (no deaths) | NA (no deaths) | NA (no deaths) | NA (no deaths) |
| Change to surgery | 0.343 | 1.38 (0.71 to 2.68) | NA | NA |
| SARS-CoV-2 infection status | | | | |
| Not suspected or detected | Reference | 1.0 | Reference | 1.0 |
| Probable SARS-CoV-2 infection | 0.033 | 2.84 (1.09 to 7.42) | 0.110 | 2.35 (0.82 to 6.72) |
| Laboratory confirmed SARS-CoV-2 infection | 0.248 | 1.71 (0.69 to 4.21) | 0.449 | 1.51 (0.52 to 4.36) |

and 8 deaths (1.2%) among 648 participants in HICs ($\chi^2=36.226$, $p<0.001$). Income group, ASA grade, chemotherapy within 90 days of the MDT, surgery within 90 days of the MDT, and tumour type were significantly associated with death at 90 days. At 12 months, there were 206 (13.0%) deaths in this cohort with 174 deaths (15.7%) among 1107 participants in LMICs, and 32 deaths (6.8%) among 474 participants in HICs ($\chi^2=23.550$, $p<0.001$). Income group, ASA grade, chemotherapy within 30 days of the MDT, immunotherapy within 30 days of the MDT

and tumour type were significantly associated with death at 12 months.

DISCUSSION

This is the largest international cohort study to date to report COVID-19 outcomes for childhood cancers. We have shown that during the COVID-19 pandemic, children with cancer are more likely to die within 30 days if infected with SARS-CoV-2, even when adjusting for changes from normal

standards of oncological care. However, the timely administration of chemotherapy is significantly associated with reduced odds of death at 30 days, 90 days and 12 months. Similar significant associations exist between timely surgery and reduced odds of death at 90 days, and timely administration of immunotherapy and reduced odds of death at 12 months. This report provides crucial information for public health policymakers to balance the benefits of providing anticancer therapy against the risks of SARS-CoV-2 infection in children with cancer.

During the COVID-19 pandemic, studies investigating COVID-19 outcomes for cancer patients have typically used 30-day mortality.^{24 31–34} The 30-day mortality from our study was 3.4% (n=71/2084). This is similar to the 30-day mortality reported by the Mukkada *et al* study: 3.8%. Their population of interest was children with cancer and SARS-CoV-2 infection. Their marginally higher death rate may reflect the impact of SARS-CoV-2 infection. Equally the high death rate observed in our study may be due to the impact of having a majority of participants from LMICs: to our knowledge, a first for global cohort studies on childhood cancers. Children with cancer in LMICs have historically had lower 5-year survival compared with their HIC counterparts,^{5 7 8} and residence in LMICs is a factor that has been shown in our study to be associated with an increased odds of death at 30 days (4.6%), 90 days (7.9%) and 12 months (15.7%).

Of note, the 30-day mortality figure in our study is substantially lower than the 24% to 30.6% 30-day mortality reported among adult cancer patients during the COVID-19 pandemic.^{31–34} This may reflect the lower risk of death in children compared with adults infected with SARS-CoV-2.³⁵ However, 30-day mortality figures for adults with cancer prior to the pandemic ranged from 3% to 10.6%.^{36–38} Therefore, there may have been a higher mortality rate at baseline in adults compared with children; comparable 30-day mortality figures for childhood cancers prior to the pandemic have not—to our knowledge—been published. A high 30-day mortality rate may reflect the aggressiveness of certain adult cancers; however, studies to date have highlighted lack of timely anticancer treatment to be a significant causative factor in driving the high rate of mortality in adult cancers.^{36–38} The use of 30-day mortality is increasingly recognised as a novel indicator to monitor quality of care in adult cancer treatment.^{36 37 39 40} However, this transition has yet to be made for childhood cancers, where there is a focus on using 5-year survival data.² Gathering a sufficient sample from one centre or even one country can take up to 5 years,² with an estimated additional 6 years required to formally publish mature 5-year survival data,^{41–43} and an average delay of 17 years before the findings is translated into clinical practice.⁴⁴ Utilising 30-day mortality may reduce the time taken to recruit, conduct and disseminate the findings from a study. Our study shows that 30-day mortality is significantly different between LMICs and HICs, and this metric can identify patient-specific and system-specific factors associated with mortality. Therefore, the utility of 30-day mortality may extend beyond that of the pandemic as a useful indicator of quality of care in childhood cancer

treatment internationally. This comes with a caveat, however, that using 30-day mortality figures that are focused on only one setting may not give a true reflection of the quality of childhood cancer treatment, for example, a hospital-focused 30-day mortality figure may increase if children who would otherwise die at home (with no palliative care) start to be brought in to hospital.

In addition, our study showed that 90-day mortality and 12-month mortality are also significantly different between LMICs and HICs. Therefore, they may prove to be other useful indicators of quality of care for WHO and GICC to monitor the progress of cancer care in LMICs. Of note, SARS-CoV-2 infection was not significantly associated with mortality at 90 days or 12 months. Given the association with 30-day mortality, this could suggest that SARS-CoV-2 infection accelerates mortality among vulnerable children with cancer, but ultimately does not change long-term mortality trends in childhood cancers. However, it is important to note that only a minority of patients underwent laboratory testing for SARS-CoV-2 infection, especially in LMICs, and, therefore, there may be an under-reporting of SARS-CoV-2 infection in our cohort, which could be leading to a misclassification bias affecting the results. Since laboratory testing only occurred for a minority of participants in LMICs, the higher odds of death among patients designated to have ‘Probable SARS-CoV-2 infection’ may be both a reflection of the impact of SARS-CoV-2 infection and infrastructural issues. Furthermore, SARS-CoV-2 infection was only recorded if it occurred within 30 days of starting anticancer therapy. Patients may have gone onto become infected with SARS-CoV-2 after 30 days, which may account in part for the increase in mortality seen in 90 days and 12 months. The absence of published 90-day and 12-month mortality figures for childhood cancers prior to the pandemic renders this difficult to ascertain. With increasing international attention on scaling-up testing for SARS-CoV-2 infection,⁴⁵ future studies can address these uncertainties.

A significant strength of this study is that it is the first international study that has been designed and powered to detect if changes from normal standards of care due to the COVID-19 pandemic have impacted outcomes in childhood cancers. A total of 201 patients (9.5%) reportedly had their care affected because of the COVID-19 pandemic. However, changes to treatment due to the COVID-19 pandemic were not significantly associated with mortality at 30 days, 90 days or 12 months. Yet, delays in treatment—regardless of the underlying reason behind them—were associated with an increased odd of death. Patients in HICs had the fastest average time from diagnosis to initial MDT management plan being made, were more likely to have a central venous catheter inserted on a chemotherapy plan being made and were more likely to have planned anticancer therapy treatment within 30 days and 90 days. These factors may be playing a role in patients in HICs having lower odds of mortality at 30 days, 90 days and 12 months. Tackling the time-lags between diagnosis and treatment are cost-effective interventions for childhood cancers.¹⁸ It is critical that interventions here focus on the unique challenges posed by each

LMIC, as extrapolation of cancer control programme experiences in HICs to LMICs is inappropriate without considering local resources and cultures.^{46 47}

There are several potential limitations to consider when interpreting our results. First, clinicians were tasked with determining whether a change to treatment was due to the COVID-19 pandemic. It is possible that response bias might have led to clinicians accounting any change to the COVID-19 pandemic. To mitigate against this bias, we requested that all data collectors attest they have only submitted new issues brought about by the pandemic. Therefore, although we are not aware of a bias towards baseline gaps in service delivery, we cannot confirm that pre-existing issues with service provision and supply chains did not contribute to the disparity in care showcased by this study. Second, participating LMIC sites tended to be tertiary hospitals, while HIC sites included a larger mix of general hospitals, paediatric hospitals and paediatric oncology hospitals (online supplemental appendix S2). There is an inherent variability in capacity for cancer care between these hospital types.⁴⁸ The inclusion of hospitals in HICs that were not specialised for the care of children with cancer may have resulted in an underestimation of the effect of the COVID-19 pandemic—including the disruptions to care—on this population in LMICs relative to HICs. Third, due to the inability to capture socioeconomic status and ethnicity consistently across a global cohort, we were unable to ascertain the effects of these factors on outcomes. Fourth, due to global data privacy rules and the need to collect this data urgently due to a new infectious threat, no patient reported outcome measures were collected. Fifth, there may have been selection bias from the type of participants lost to follow-up. Sixth, given the small number of children in the study who had laboratory-confirmed SARS-CoV-2 infection or who were started on immunotherapy, the effect sizes for these variables may not reflect a true effect (ie, the findings may be false positives). Finally, this study was unable to collect data from patients who failed to reach a healthcare service provider, and, therefore, it might not reflect the true impact of the pandemic on oncological outcomes.

Childhood cancer is a highly curable disease when healthcare systems provide timely, accurate diagnoses and appropriate therapy. In our study, we have shown for the first time that paediatric cancer survival rate is significantly lower in the short term in LMICs than in HICs. This disparity may be due to health system challenges such as limited access to early detection and lack of effective treatment and care.

Acknowledgements Thank you to the University of Oxford Medical Sciences Division IT Services Systems Team (MSDIT Systems Team) for the REDCap administration and management. Thank you to the representatives from the College of Surgeons of Southern, East and Central Africa (COSECSA), the Global Children's Initiative for Surgery (GICS), the Pan-African Paediatric Surgical Association (PAPSA), the International Society of Paediatric Oncology (SIOP), and the International Society of Paediatric Surgical Oncology (IPSO) who made this study possible. Thank you to all our collaborators from our country leads to the members of our local mini-teams for driving this study forward.

Collaborators Global Children's NCDs Collaborative: Steering committee: Soham Bandyopadhyay [UK], Noel Peter [UK] (Asia Lead), Kokila Lakhoo [UK], Simone de Campos Vieira Abib [Brazil] (South America Lead), Hafeez Abdelhafeez [Sudan]

(Africa and Middle East Lead), Shaun Wilson [UK] (Australasia Lead), Max Pacht [UK] (Europe and North America Lead), Benjamin Martin [UK] (Europe Lead), Sonal Nagras [Australia] (Australasia Lead), and Mihir Sheth [India]. Operational committee: Catherine Dominic [UK], Suraj Gandhi [UK], Divya Parwani [India], Rhea Raj [UAE], Diella Munezero [Burundi], Rohini Dutta [India], Nsimire Mulanga Roseline [DRC], Kellie McClafferty [UK], Armin Nazari [UK], Smriti Sriram [UK], Sai Pillariseti [UK], King-David Nweze [UK], Aishwarya Ashwinee [Grenada], Gul Kalra [India], Poorvaprabha Patil [India], Priyansh Nathani [India], Khushman Kaur Bhullar [India], Muhammed Elhadi [Libya], Maryam Khan [Pakistan], Nehal Rahim [Pakistan], Shweta Madhusudanan [UK], Joshua Erhabor [UK], Manasi Shirke [UK], Aishah Mughal [UK], Darica Au [UK], Mahan Salehi [UK], Sravani Royyuru [UK], Mohamed Ahmed [Egypt], Syeda Namayah Fatima Hussain [Pakistan], Daniel Robinson [UK], Anna Casey [UK], Mehdi Khan [UK], Alexandre Dukundane [Rwanda], Kwizera Festus [Rwanda], Vaishnavi Govind [Grenada], Rohan Pancharatnam [UK], Lorraine Ochieng [UK], Elliott H Taylor [UK], Hritik Nautiyal [UK], Marta de Andres Crespo [UK], Somy Charuvila [UK], and Alexandra Valetopoulou [UK]. Writing committee: Soham Bandyopadhyay [UK], Amanpreet Brar [Canada], Hira Zuberi [Pakistan], Imane Ammouze [Morocco], Dhruva Ghosh [India], Nitin James Peters [India], Noel Peter [UK], and Kokila Lakhoo [UK]. Statistics committee: Soham Bandyopadhyay [UK] and Mihir Sheth [India]. Local teams: Abubakar Tafawa Balewa University Teaching Hospital, Nigeria: Kefas John Bwala, AM Umar, Abdurahaman Aremu, Dauda E. Suleiman, Tybat Aliyu. Aga Khan University Hospital, Pakistan: Ayesha Saleem, Muhammad Arshad, Kashaf Turk, Sadaf Altaf. Ahmadu Bello University Teaching Hospital, Nigeria: Oluseyi Oyebo Ogunsua, Tunde Talib Sholadoye, Musliu Adetola Tolani, Yakubu Alfa, Keffi Mubarak Musa. AIC Kijabe Hospital, Kenya: Eric Mwangi Irungu, Ken Muma, Sarah Muma, Michelle Obat. Ain Shams Hospitals "El-Demerdash", Egypt: Yousef Sameh Badran. Al-Basheer Hospital, Jordan: Abdulrahman Ghassan Qasem, Faris Ayastra, Reema Alnajjar. Al-Hussein University Hospital, Egypt: Mohamed Abdel-Maboud, Abdelrahman Bahaa, Ayat M. Saadeldin, Mohamed Adwi, Mahmoud Adly, Abdallah Elshenawy. Alder Hey Children Hospital, UK: Amer Harky, Leanne Gentle, Kirstie Wright, Jessica Luyt, Olivia White, Charlotte Smith, Nathan Thompson, Thomas Smith, Imogen Harrison. All India Institute of Medical Sciences (AIIMS), Bhubaneswar, India: Santosh Kumar Mahalik. All India Institute of Medical Sciences (AIIMS), Rishikesh, India: Rajat Piplani, Enono Yhoshu, Manoj Gupta, Uttam Kumar Nath, Amit Sehrawat, Rajkumar K S, Vivek Singh. Augusta Victoria Hospital, Palestine: Sadi A. Abukhalaf. Bangladesh Shishu Hospital & Institute, Bangladesh: Ashrarur Rahman Mitul, Sabbir Karim, Nazmul Islam. Benghazi pediatric hospital, Libya: Sara Kader Alsaeti, Fatma Saleh Benkhial, Mohammed Miftah Faraj Almihashhish, Eman Salem Muftah Burzeiza, Hend Mohammed Masoud, Mabroukah Saied Alshamikh, Raja Mari Mohammed Nasef, Fatma Mohammed Masoud. Birmingham Children's Hospital, UK: William B Lo, Nyararai Togarepi, Elaine Carrolan, Benjamin Martin, Max Pacht, Benjamin J O'Sullivan. Borg El Arab University Hospital, Egypt: Mohamed Hassanin, Ahmed Saleh, Mahmoud Bassiony, Mostafa Qatora, Mohamed Bahaaeldin, Shady Fadel, Yasmine El Chazli. Centre Anti-Cancer, Batna, Algeria: Anfel Bouderbala, Kamel Hamizi, Safia Lorabi, Mehdi Anouar Zekkour, Rima Rahmoun, Boutheyna Drid, Salma Naje Abu Teir. Centre hospitalier universitaire de Batna, Algeria: Safia Lorabi, Mohamed Yazid Kadir, Yasmine Zerizer, Nacer Khernane, Brahim Saada. Centre Hospitalo-Universitaire Ibn Sina de Rabat (CHIS), Morocco: Imane Ammouze, Yahya Elkaoune, Hajar Moujtahid, Ghita Chaoui, Hajar Benaouda, Meryem Gounni, Narjiss Aji, Laila Hessissen. Centro Hospitalar Universitário de São João, Portugal: Joana Mafalda Monteiro, Susana Nunes, Maria do Bom-Sucesso. Children's Hospital of Wisconsin, United States of America: Dave R. Lal, Brian T. Craig, Kerri Beckett. Chittagong Research Institute For Children Surgery, Bangladesh: Tahmina Banu, Md Afruzul Alam, Orindom Shing Pulock, Tasmiah Tahera Aziz. Christian Medical College & Hospital, Ludhiana, India: Vishal Michael, M Joseph John, William Bhatti, Bobby John, Swati Daniel, Jyoti Dhiman, Hunar Mahal, Atul Surroy. Clinic for Neurosurgery, Clinical Center of Serbia, Serbia: Rosanda Ilic, Danica Grujicic, Tijana Nastasovic, Igor Lazic, Mihailo Milicevic, Vladimir Bascarevic, Radovan Mijalcic, Vuk Scepanovic, Aleksandar Stanimirovic, Aleksandra Paunovic, Ivan Bogdanovic. Dayanand Medical College & Hospital Ludhiana, India: Shruti Kakkar, Shaina Kamboj, Suraj Singh. Dhaka Medical College Hospital, Bangladesh: Shahnoor Islam, AKM Amirul Morshed, A. K. M. Khairul Basher, Mehnaz Akter, S. M. Rezanur Rahman, Zannat Ara, Mohammed Tanvir Ahammed, Tania Akter, Kamrun Nahar, Fatema Sayed, Ashfaque Nabi, Md. Asif Iqbal, Md. Masud Rana, Md. Asaduzzaman, Md. Hasanuzzaman. Dr. Lutfi Kirdar Kartal Training and Research Hospital, Turkey: Kemal Tolga Saracoglu, Elif Akova, Evren Aydogmus, Bekir Can Kendirlioglu, Tufan Hicdonmez. Dubai Hospital, United Arab Emirates: Arshiya Adhnon, Asim Noor Rana, Hani Humad, Anjan Madasu. El Safa Hospital, Egypt: Ahmed Y Azzam, Mohammed A Azab. El Sheikh Zayed Specialized Hospital, Egypt: Sherief Ghozy, Alzhraa Salah Abbas. El-Salam Hospital, Egypt: Monica Dobs, Mohamed Atef Mohamed Ghamry, Mohammed Alhendy.

Faculty of Medicine, University of Porto, Portugal: Joana Monteiro. Federal Medical Center, Abeokuta, Nigeria: Olanrewaju Moses. Federal Medical Center, Lokoja, Nigeria: Ibiyeye Taiye Taibat, Taiwo Jones, Kalu Ukoha, Olagundoye Goke, Okorie Ikechukwu. Federal Teaching Hospital Ido-Ekiti, Nigeria: Abiodun Idowu Okunlola. Frere Hospital, South Africa: Milind Chitnis, Helga Nauhaus, Danelle Erwee. Gloucestershire Hospitals NHS Foundation Trust, United Kingdom: Robyn Brown, Agata Chylinska, Robin Simpson, Prasanna Gomes, Noel Peter. GPACI - Grupo de Pesquisa e Assistência ao Câncer Infantil, Brazil: Marco Aurelio Ciriaco Padilha, Elvécio Pereira de Oliveira Junior, Lucas Garschagen de Carvalho, Fabiola Leonelli Diz. Helwan University Hospital, Egypt: Mohamed El Kassas, Usama Eldaly, Ahmed Tawheed, Mohamed Abdelwahab. Hôpital des Spécialités ONO, Morocco: Oudrhiri Mohammed Yassaad, Bechri Hajar, El Ouahabi Abdessamad, Arkha Yasser, Hessissen Laila. Ibn-Al-Atheer Teaching Hospital, Mosul, Iraq: Farah Sameer Yahya (Department of Pediatrics, College of Medicine, University of Mosul, Mosul, Iraq), Yasir Al-Agele. Indira Gandhi Institute of Medical Sciences (IGIMS), India: Sandip Kumar Rahul, Vijayendra Kumar, Digamber Chaubey. Instituto Nacional de Enfermedades Neoplásicas, Peru: María Teresa Peña Gallardo, Jacqueline Elizabeth Montoya Vásquez, Juan Luis García León, Sebastián Shu Yip. Ipswich Hospital NHS Trust, UK: Georgios Karagiannidis. Istanbul University, Turkey: Rejin Kebudi, Sema Bay Buyukkapu. Jawaharlal Institute of Postgraduate Medical Education and Research, India: Krishna Kumar Govindarajan, Kumaravel Sambandan, Smita Kayal, Gunaseelan Karunanithi, Bikash Kumar Naredi, Bibekanand Jindal. John Radcliffe Hospital, United Kingdom: Mahmud Lami, Matthew H V Byrne, Duha Jasim, Harmit Ghattaura, Soham Bandyopadhyay, Kokila Lakhoo. Johns Hopkins Hospital Bloomberg Children's Hospital, United States of America: Eric W Etchill, Daniel Rhee, Stacy Cooper, Kevin Crow, Morgan Drucker, Megan Murphy, Benjamin Shou, Alan Siegel. Kanuni Sultan Süleyman Research and Training Hospital, Turkey: Yasin Kara, Gül Nihal Özdemir. Kasr Al Ainy Hospital, Egypt: Mahmoud Elfiky, Ehab El Refaee. Khoula Hospital, Oman: John George Massoud. King Abdullah University Hospital, Jordan: Ayah Bassam Ibrahim, Ruaa Bassam Ibrahim, Faris Abu Za'nouneh, Ranya M. Baddourah, Toqa Fahmawee, Ayah Al-Shraideh. King Fahd Central Hospital, Saudi Arabia: Ghazwani Salman, Ehab Alameer (Jazan University), Al-Mudeer Ali, Ghazwani Yahia, Khozairi Waleed. King George's Medical University, India: Ahmad Ozair, Ankur Bajaj, Bal Krishna Ojha, Kaushal Kishor Singh, Atique Anwar, Vinay Suresh. King Hussein Cancer Center, Jordan: Mohamad K. Abou Chaar, Iyad Sultan, Khalil Ghandour, Shaima' Al-Dabaibeh, Ammar Al-Basiti, Hazim Ababneh, Omaima El-Qurneh. King Salman Armed Forces Hospital, Saudi Arabia: Yousef Alalawi, Ahmad Al Ayed, Ehab Hanafy, Naif Al Bolowi. Women's and Children's Hospital, Singapore: Amos HP Loh, Anette S Jacobsen Heidi Barola Aubrey L. Pagaduan Jingdan Fan. Lagos University Teaching Hospital, Nigeria: Olumide Abiodun Elebute, Adesoji O. Ademuyiwa Christopher O. Bode Justina O. Seyi-Olajide Oluwaseun Ladipo-Ajayi Felix M. Alakaloko George C. Ihediwa Kareem O. Musa, Edamisan O. Temiye, Olufemi Oni, Adeseye M. Akinsete. Lahore General Hospital, Pakistan: Janita Zarrish, Ramsha Saleem, Soha Zahid, Atiqa Amirali, Ahsan Nadeem, Sameer Saleem Tebha, Zonaira Qayyum, Sana Tahir, Anneqa Tahir, Rabbey Raza Khan, Aysha Mehmood, Iqra Effendi. Liaquat National Hospital and Medical College, Pakistan: Muhammad Arshad, Taimur Ifitikhar Qureshi, Pooja Kumari. Mansoura University Hospitals, Egypt: Mohamed Bonna, Khaled Mamdouh, Mohamed Atef, Mohamed Faried. Mater Dei Hospital, Sir Anthony Mamo Oncology Centre, Malta: Victor Calvagna, Nathalie Galea, Ariana Axiq. Mayo Clinic, United States of America: Matthew R Schuelke, Jake A. Kloeber, Robert L. Owen, Alexander S. Roth, Catherine Yang, J. Hudson Barnett, Lucien P. Jay, Kirk David Wyatt, Paul J. Galardy, Mbeya Zonal Referral Hospital, University of Dar es Salaam, Tanzania: Bernard Mbwele, Irene Nguma, Moshi Moshi Shabani, Amani Twaha, Bilal Matola. Medical University of Pecs, Department of Paediatrics, Hungary: Agnes Vojcek. Menoufia University Hospital, Egypt: Mahmoud Maher Abdelnaby Alrahawy, Seham M Ragab, Abdallah R Allam, Eman Ibrahim Hager, Abdelrahman Azzam, Ammar Ayman. Ministry of Health Marmara University Pendik Research and Application Hospital, Turkey: Kivılcım Karadeniz Cerit, Adnan Dağçınar, Tümay Umuroğlu, Ayten Saraçoğlu, Mustafa Sakar, Can Kıvrak, Gül Çakmak. MISR Cancer Centre, Egypt: Ibrahim Sallam, Gamal Amira, Mohamed Sherief, Ahmed Sherif. National Cancer Institute, Brazil: Simone de Oliveira Coelho, Arissa Ikeda, Licia Portela, Marianne Monteiro Garrigo, Ricardo Vianna de Carvalho, Fernanda Lobo, Sima Ester Ferman, Fernanda Ferreira da Silva Lima. National Cancer Institute, Sudan: Moawia Mohammed Ali Elhassan, Nada Osman Yousif Elhaj, Hytham K. S. Hamid. National Hospital, Nigeria: Emmanuel A. Ameh, Vincent E. Nwatah, Adewumi B. Oyesakin. Nnamdi Azikiwe University Teaching Hospital, Nigeria: Andrew Nwankwo Osuigwe, Okechukwu Hyginus Ekwunife, Chisom Adaobi Nri-Ezedi, Eric Okechukwu Umeh. Ola During Children's Hospital, Sierra Leone: Nellie Bell. Olabisi Onabanjo University Teaching Hospital, Nigeria: Ibukunolu Olufemi Ogundele, Abiodun Folashade Adekanmbi, Olubunmi Motunrayo Fatungase, Olubunmi Obafemi Obadaini. Ondokuz Mayıs Üniversitesi, Turkey: Sarah Al-Furais, Humaida Hemlae, Sreyllis Nay. Pantai

Jerudong Specialist Centre, Brunei: John Mathew, R M Jeffri Ismail. Pediatric Oncology Institute – GRAACC, Brazil: Simone de Campos Vieira Abib, Fabianne Altruda de Moraes Costa Carlesse, Mayara Caroline Amorim Fanelli, Fernanda Kelly Marques de Souza. Policlinico Umberto I, Sapienza University of Rome, Italy: Pierfrancesco Lapolla, Andrea Mingoli, Denis Cozzi, Anna Maria Testi, Paolo Musiu, Paolo Sapienza, Gioia Brachini, Martina Zambon, Simona Meneghini, Pierfranco Cicerchia, Bruno Cirillo. Post Graduate Institute of Medical Education and Research, Chandigarh, India: Manjul Tripathi, Nitin James Peters, Sandeep Mohindra, Vishal Kumar, Ninad R Patil, Richa Jain, Renu Madan, Madhivanan Karthigeyan, Pravin Salunke. Prince Mohammed bin Nasser Hospital, Jazan, Saudi Arabia: Ghazwani Salman. Prince Sattam Bin Abdulaziz University, Saudi Arabia Gopal Nambi. Raparin Pediatric Teaching Hospital, Iraq: Abdulrahman Omar Taha. RIPAS Hospital, Brunei: Janice Hui Ling Wong, Norehan Johari, Anas Shikha, Win Sabai Phyu Han, Zahidah Ahmad, Yen Yan Lim, Roserahayu Idros, Noorainun Mohd Yusof, David Nelson Jaisingh. Saadna Mohamed Abdenour, Algeria: Aouabed Nesrine, Bouaoud Souad, Mebarki Malika, Bioud Belkacem. Salmaniya Medical Complex, Bahrain: Fayza Haider, Fatema Naser Al Fayed. Shahid Baghaei Hospital, Iran: Fakher Rahim. Sheba Medical Center/Tel HaShomer Hospital, Israel: Elana Kleinman, Taylor Ibelli, Emily Hamilton, Rochelle Fayngor, Tzvi Najman, Gideon Karplus, Etai Adam, Daniella Melamed, Cecilia Paasche. St. George's Hospital, UK: Amir Labib. Sultan Qaboos University Hospital, Muscat Sultanate of Oman: Farman Ali Laghari, Dhruva Ghosh, Zainab Al Balushi, Abdulhakim Awadh Salim Al-Rawas, Ali Al Sharqi, Ammar Saif Al Shabibi, Ismail Al Bulushi, Muna Alshahri, Abdulrahman AlMirza, Ola Al Hamadani, Jawaher Al Sharqi, Anisa Al Shamsi, Bashar Dawud, Sareya Al Sibai. Tamale Teaching Hospital, Ghana: Alhassan Abdul-Mumin, Halwani Yaninga Fuseini, Peter Gyamfi Kwarteng, Abubakari Bawa Abdulai, Sheba Mary Pognaa Kunfah, Gilbert B. Bonaana, Stephanie Ajinkpang, Edmund M. Der, Francis A. Abantanga, Mary Joan Kpiniong, Kingsley Aseye Hattor, Kingsley Appiah Bimpong. Tanta University Hospital, Egypt: Mohamed Elbahnasawy, Sherief Abdelsalam, Ahmed Samir. The Hospital for Sick Children, Canada: Reto M. Baertschiger, Amanpreet Brar, Andreea C, Matei, Augusto Zani. The Indus Hospital, Pakistan: Lubna Samad, Hira Khalid Zuberi, Kishwer Nadeem, Naema Khayyam, Fatima Ambreen Imran, Nida Zia, Sadia Muhammad, Muhammad Rafie Raza, Muhammad Rahil Khan. Tishreen University Hospital, Syria: Alaa Hamdan, Ammar Omran, Ahmed Moussa, Bardisan Gawrieh, Hassan Salloum, Alaa Ahmed, Abdeljawad Mazloun, Ali Abodest, Nisreen Ali, Munawar Hraib, Victor Khoury, Abdulrahman Almjersah, Mohammad Ali Deeb, Mohammad Ahmad Almahmod Alkhaili, Akram Ahmed, Waseem Shater, Ali Farid Alelayan, Alaa Guzman. Tobruk Medical Centre, Libya: Ahmad Bouhuwaish, Alqasim Abdulkarim. Tripoli University Hospital, Libya: Eman Abdulwahed, Marwa Biala, Reem Ghamgh, Amani Alamre, Marwa Shefff, Asmaa A. M. Albanna, Hoda Tawel. Unit of Paediatric and Adolescent Haematology and Oncology, 2nd Department of Paediatrics, Aristotle University of Thessaloniki, University General Hospital AHEPA, Greece: Emmanuel Hatzipantelis, Athanasios Tragiannidis, Eleni Tsoitridou, Assimina Galli-Tsinopoulou. Universiti Kebangsaan Malaysia Medical Centre, Malaysia: Dayang Anita Abdul Aziz, Zarina Abdul Latiff, Hamidah Alias, C-Khai Loh, Doris Lau, Azrina Syarizal Khutubul Zaman, University College Hospital (UCH), Nigeria: Taiwo Akeem Lawal, Kelvin Ifeanyi-chukwu Egbuchulem, Olakayode Olaolu Ogundoyin, Isaac Dare Olulana, Biobebe J. Brown, Oluwasegun Joshua Afolaranmi, AbdulBasit Fehintola. University Hospital Hamburg-Eppendorf, Germany: Annika Heuer, Christine Nitschke, Michael Boettcher, Matthias Priemel, Lennart Viezens, Martin Stangenberg, Marc Dreimann, Alonja Reiter, Jasmin Meyer, Leon Köpke, Karl-Heinz Frosch. University of Abuja Teaching Hospital, Nigeria: Samson Olori, Uduak Offiong, Philip Mari Mshelbwa, Fashie Andrew Patrick, Aminu Muhammed Umar, Otene ThankGod N. University of Ilorin Teaching Hospital, Nigeria: Abdurashed A Nasir, Kazeem O. O. Ibrahim, Dupe S. Ademola-Popoola, Olayinka T. Sayomi, Alege Abdurrrzaq, Ademola A. Adeyeye, Khadijah O. Omokanye, Lukman O Abdur-Rahman, Olubisi Olutosin Bamidele, Shakirullah AbdulAzeez, Aminat Akinoso, Michael O. Adegboye. University of Malaya Medical Centre, Malaysia: Shireen Anne Nah, Yuki Julius Ng, Syukri Ahmad Zubaidi, University of Texas Medical Branch, United States of America: Murad Almasri, Sara Ali, Rasaan Olaosebikan, Akila Muthukumar. University Teaching Hospital, Zambia: Patricia Shinondo, Amon Ngongola, Bruce Bvulani, Azad Patel, Usman Fandofiyi University Teaching Hospital, Nigeria: Abdullahi Nuhu-Koko, Baba Jibrin, Ajiboye L. Olalekan, Christopher S. Lukong, Ezekiel I. Ajayi. Vall d'Hebron University Hospital, Spain: Gabriela Guillén, Sergio López, José Andrés Molino, Pablo Velasco, Wingat Royal Hospital, Egypt: Omar Elmandouh, Omar Hamam, Rim Elmandouh. Yale New Haven Hospital, United States of America: Nensi Melissa Ruzgar, Rachel Levinson, Shashwat Kala, Sarah Ullrich, Emily Christison-Lagay. Zagazig University Hospital, Egypt: Aya Sabry Mortada, Mahmoud Ahmed Ebada, Eman Seif Alnaser Solimam, Khaled Abualkher, Amr Mohammed Elsayed Yousf, Mohamed Mohamed Holail, Reem Mohamed Almowafy. National/Regional Leads: Algeria: Salah Eddine Oussama Kacimi, Bahrain: Fayza Haider, Bangladesh: Tahmina Banu, Ashrarur

Rahman Mitul, Brazil: Simone de Campos Vieira Abib, Brunei: Janice Hui Ling Wong, Canada: Reto Baertschiger, Egypt: Essam Elhalaby, Muath Alser, Mahmoud M. Saad, France: Luca Pio, Germany: Guido Seitz, Judith Lindbert, Ghana: Francis Abantanga, Greece: Georgios Tsoulfas, Asimina Galli-Tsinopoulou, Hungary: Agnes Vojcek, India: Dhruva Ghosh, Nitin James Peter, Ankur Bajaj, Vrisha Madhuri, Ravi Kishore, Iran: Maryam Ghavami Adel, Iraq: Abdulrahman Omar Taha, Italy: Calogero Virgone, Francesco Pata, Gaetano Gallo, Jordan: Mohammad K. Abou Chaar, Faris Ayastra, Israel: Elana Kleinman, Taylor Ibelli, Kenya: Eric Mwangi Irungu, Libya: Muhammed Elhadi, Malaysia: Shireen Anne Nah, Dayang Anita Abdul Aziz, Malta: Victor Calvagna, Morocco: Outani Oumaima, Zineb Bentounsi, Hajar Moujtahid, Nigeria: Adesoji Ademuyiwa, Oman: Dhruva Nath Ghosh, Pakistan: Muhammad Arshad, Lubna Samad, Peru: Lily Saldana, Portugal: Jan Godzinsky, Saudi Arabia: Abdelbasit Ali, Ehab Alameer, Serbia: Dragana Janic, Sierra Leone: Mohamed Bella Jalloh, Nellie Bell, Singapore: Annette Jacobsen, Chan Hon Chui, South Africa: Milind Chitnis, Spain: Israel Fernandez Pineda, Lucas Krauel, Maricarmen Olivos, Sudan: Waha Rahama, Hazim Elfatih, Switzerland: Raphael N. Vuille-dit-Bille, Syria: Alaa Hamdan, Turkey: Arda Isik, United Arab Emirates: Asim Noor Rana, United Kingdom: Kokila Lakhoo, Kate Cross, Max Pacht, United States of America: Andrea Hayes-Jordan, Roshni Dasgupta, Zambia: Patricia Shinondo, Amon Ngongola, Middle-East and North Africa: Mohamedraed Elshami.

Contributors This is a paper produced under a collaborative authorship model: Global Health Research Group on Children's Non-Communicable Diseases Collaborative. All authors are solely listed under the collaborative authorship. A full authorship list can be found in Appendix S2. KL is the author acting as guarantor.

Funding Donation from the Kids Operating Room Research Fund.

Competing interests None declared.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not applicable.

Ethics approval All participating centres have gained study approval to participate according to their local institutional ethical regulations. Examples of ethical approval: Brunei Medical and Health Research & Ethics Committee (MHREC/MOH/2020/14/2); Yale Human Research Protection Program Institutional Review Board (2000028852); and Tanta University Research Ethics Committee (33965/7/20).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

Author note The reflexivity statement for this paper is linked as an online supplemental file 1.

REFERENCES

- Birch JM, Marsden HB, Jones PH, *et al*. Improvements in survival from childhood cancer: results of a population based survey over 30 years. *Br Med J* 1988;296:1372.
- Saletta F, Seng MS, Lau LMS. Advances in paediatric cancer treatment. *Transl Pediatr* 2014;3:156–82.
- Pritchard-Jones K, Pieters R, Reaman GH, *et al*. Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries. *Lancet Oncol* 2013;14:e95–103.
- SEER Statistics. Cancer statistics review, 1975–2015. Available: https://seer.cancer.gov/archive/csr/1975_2015/ [Accessed 02 Oct 2020].
- Bhakta N, Force LM, Allemani C, *et al*. Childhood cancer burden: a review of global estimates. *Lancet Oncol* 2019;20:e42–53.
- The Lancet Child Adolescent Health. Fighting childhood cancer with data. *Lancet Child Adolesc Health* 2019;3:585.
- Allemani C, Matsuda T, Di Carlo V, *et al*. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. *Lancet* 2018;391:1023–75.
- Lam CG, Howard SC, Bouffet E, *et al*. Science and health for all children with cancer. *Science* 2019;363:1182–6.
- Gupta S, Howard SC, Hunger SP. Treating Childhood Cancer in Low- and Middle-Income Countries. In: *Disease Control Priorities, Third Edition (Volume 3): Cancer. The World Bank*, 2015: 121–46.
- Howard SC, Metzger ML, Wilimas JA, *et al*. Childhood cancer epidemiology in low-income countries. *Cancer* 2008;112:461–72.
- Wilson ML, Atun R, DeStigter K, *et al*. The Lancet Commission on diagnostics: advancing equitable access to diagnostics. *Lancet* 2019;393:2018–20.
- Ribeiro RC, Steliarova-Foucher E, Magrath I, *et al*. Baseline status of paediatric oncology care in ten low-income or mid-income countries receiving my child matters support: a descriptive study. *Lancet Oncol* 2008;9:721–9.
- Cohen P, Friedrich P, Lam C, *et al*. Global access to essential medicines for childhood cancer: a cross-sectional survey. *J Glob Oncol* 2018;4:1–11.
- Sullivan R, Alatise OI, Anderson BO, *et al*. Global cancer surgery: delivering safe, affordable, and timely cancer surgery. *Lancet Oncol* 2015;16:1193–224.
- Rodriguez-Romo L, Olaya Vargas A, Gupta S, *et al*. Delivery of pediatric cancer care in Mexico: a national survey. *J Glob Oncol* 2018;4:1–12.
- Magrath I, Steliarova-Foucher E, Epelman S, *et al*. Paediatric cancer in low-income and middle-income countries. *Lancet Oncol* 2013;14:e104–16.
- Silbermann M, Al-Hadad S, Ashraf S, *et al*. Mecc regional initiative in pediatric palliative care. *J Pediatr Hematol Oncol* 2012;34:S1–11.
- Atun R, Bhakta N, Denburg A, *et al*. Sustainable care for children with cancer: a Lancet oncology Commission. *Lancet Oncol* 2020;21:e185–224.
- World Health Organization. WHO global initiative for childhood cancer: an overview; 2018.
- Zhu N, Zhang D, Wang W, *et al*. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med* 2020;382:727–33.
- World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. Available: <https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020> [Accessed 03 May 2020].
- Millen GC, Arnold R, Cazier J-B, *et al*. Severity of COVID-19 in children with cancer: report from the United Kingdom paediatric coronavirus cancer monitoring project. *Br J Cancer* 2021;124:754–9.
- GBD 2017 Childhood Cancer Collaborators. The global burden of childhood and adolescent cancer in 2017: an analysis of the global burden of disease study 2017. *Lancet Oncol* 2019;20:1211–25.
- Mukkada S, Bhakta N, Chantada GL, *et al*. Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCO): a cohort study. *Lancet Oncol* 2021;22:1416–26.
- Graetz D, Agulnik A, Ranadive R, *et al*. Global effect of the COVID-19 pandemic on paediatric cancer care: a cross-sectional study. *Lancet Child Adolesc Health* 2021;5:332–40 <http://www.thelancet.com/article/S2352464221000316/fulltext>
- Vasquez L, Sampor C, Villanueva G, *et al*. Early impact of the COVID-19 pandemic on paediatric cancer care in Latin America. *Lancet Oncol* 2020;21:753–5.
- Peter N, Bandyopadhyay S, Lakhoo K, *et al*. Impact of the COVID-19 pandemic on paediatric patients with cancer in low-income, middle-income and high-income countries: protocol for a multicentre, international, observational cohort study. *BMJ Open* 2021;11:e045679.
- Steliarova-Foucher E, Stiller C, Lacour B, *et al*. International classification of childhood cancer, third edition. *Cancer* 2005;103:1457–67.
- Gupta S, Aitken JF, Bartels U, *et al*. Paediatric cancer stage in population-based cancer registries: the Toronto consensus principles and guidelines. *Lancet Oncol* 2016;17:e163–72.
- World Bank. World bank country and lending groups, 2021. Available: <https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups> [Accessed 10 Jul 2021].

- 31 Lee LYW, Cazier J-B, Starkey T, *et al.* COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. *Lancet Oncol* 2020;21:1309–16.
- 32 Lee LY, Cazier J-B, Angelis V, *et al.* COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. *Lancet* 2020;395:1919–26.
- 33 Russell B, Moss CL, Shah V, *et al.* Risk of COVID-19 death in cancer patients: an analysis from Guy's cancer centre and King's College hospital in London. *Br J Cancer* 2021;125:939–47.
- 34 Assaad S, Zrounba P, Cropet C, *et al.* Mortality of patients with solid and haematological cancers presenting with symptoms of COVID-19 with vs without detectable SARS-COV-2: a French nationwide prospective cohort study. *Br J Cancer* 2021;125:658–71.
- 35 Bhopal SS, Bagaria J, Olabi B, *et al.* Children and young people remain at low risk of COVID-19 mortality. *Lancet Child Adolesc Health* 2021;5:e12–13.
- 36 Khoja L, McGurk A, O'Hara C, *et al.* Mortality within 30 days following systemic anti-cancer therapy, a review of all cases over a 4 year period in a tertiary cancer centre. *Eur J Cancer* 2015;51:233–40.
- 37 Wallington M, Saxon EB, Bomb M, *et al.* 30-Day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study. *Lancet Oncol* 2016;17:1203–16.
- 38 Burgers JA, Damhuis RA. 30-Day mortality after the start of systemic anticancer therapy for lung cancer: is it really a useful performance indicator? *ERJ Open Res* 2018;4. doi:10.1183/23120541.00030-2018. [Epub ahead of print: 05 11 2018].
- 39 Department of Health. *Improving Outcomes: A Strategy for Cancer*; 2011.
- 40 Mort D, Lansdown M, Smith N, *et al.* *For better, for worse?* 2008.
- 41 Matloub Y, Bostrom BC, Hunger SP, *et al.* Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the children's Oncology Group. *Blood* 2011;118:243.
- 42 Woessmann W, Seidemann K, Mann G, *et al.* The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM group study NHL-BFM95. *Blood* 2005;105:948–58.
- 43 Lannering B, Rutkowski S, Doz F, *et al.* Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. *J Clin Oncol* 2012;30:3187–93.
- 44 Morris ZS, Wooding S, Grant J. The answer is 17 years, what is the question: understanding time lags in translational research. *J R Soc Med* 2011;104:510.
- 45 Mercer TR, Salit M. Testing at scale during the COVID-19 pandemic. *Nat Rev Genet* 2021;22:415–26.
- 46 Belkacemi Y, Grellier N, Ghith S, *et al.* A review of the International early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries. *Eur J Cancer* 2020;135:130–46.
- 47 Adegboyega G, Ozair A, Kanmounye US, *et al.* Letter: is the Stupp protocol an expensive and Unsustainable standard of care for glioblastoma in low- and middle-income country settings? A call to action! *Neurosurgery* 2021;89:E249–51.
- 48 Richards M. Children's Cancer Services: A review on behalf of NHS England 2019/20, 2020. NHS England. Available: <https://www.england.nhs.uk/wp-content/uploads/2020/01/board-meeting-item-9-update-on-specialised-services-c-appendix-2.pdf> [Accessed 08 Dec 2021].

Appendix S2: Participating Centres

Abubakar Tafawa Balewa University Teaching Hospital, Nigeria
Aga Khan University Hospital, Pakistan
Ahmadu Bello University Teaching Hospital, Nigeria
AIC Kijabe Hospital, Kenya
Ain Shams Hospitals "El-Demerdash", Egypt
Al-Basheer Hospital, Jordan
Al-Hussein University Hospital, Egypt
Alder Hey Children Hospital, UK
All India Institute of Medical Sciences (AIIMS), Bhubaneshwar, India
All India Institute of Medical Sciences (AIIMS), Rishikesh, India
Augusta Victoria Hospital, Palestine
Bangladesh Shishu Hospital & Institute, Bangladesh
Benghazi pediatric hospital, Libya
Birmingham Children's Hospital, UK
Borg El Arab University Hospital, Egypt
Centre Anti-Cancer, Batna, Algeria
Centre hospitalier universitaire de Batna, Algeria
Centre Hospitalo-Universitaire Ibn Sina de Rabat (CHIS), Morocco
Centro Hospitalar Universitário de São João, Portugal
Children's Hospital of Wisconsin, United States of America
Chittagong Research Institute For Children Surgery, Bangladesh
Christian Medical College & Hospital, Ludhiana, India
Clinic for Neurosurgery, Clinical Center of Serbia, Serbia
Dayanand Medical College & Hospital Ludhiana, India
Dhaka Medical College Hospital, Bangladesh
Dr. Lutfi Kirdar Kartal Training and Research Hospital, Turkey
Dubai Hospital, United Arab Emirates
El Safa Hospital, Egypt
El Sheikh Zayed Specialized Hospital, Egypt
El-Salam Hospital, Egypt
Faculty of Medicine, University of Porto, Portugal
Federal Medical Center, Abeokuta, Nigeria
Federal Medical Center, Lokoja, Nigeria
Federal Teaching Hospital Ido-Ekiti, Nigeria
Frere Hospital, South Africa
Gloucestershire Hospitals NHS Foundation Trust, United Kingdom
GPACI - Grupo de Pesquisa e Assistência ao Câncer Infantil, Brazil
Helwan University Hospital, Egypt
Hôpital des Spécialités ONO, Morocco
Ibn-Al-Atheer Teaching Hospital, Mosul, Iraq
Indira Gandhi Institute of Medical Sciences (IGIMS), India
Instituto Nacional de Enfermedades Neoplásicas, Peru
Ipswich Hospital NHS Trust, UK
Istanbul University, Turkey
Jawaharlal Institute of Postgraduate Medical Education and Research, India
John Radcliffe Hospital, United Kingdom
Johns Hopkins Hospital Bloomberg Children's Hospital, United States of America
Kanuni Sultan Süleyman Research and Training Hospital, Turkey

Kasr Al Ainy Hospital, Egypt
Khoula Hospital, Oman
King Abdullah University Hospital, Jordan
King Fahd Central Hospital, Saudi Arabia
King George's Medical University, India
King Hussein Cancer Center, Jordan
King Salman Armed Forces Hospital, Saudi Arabia
KK Women's and Children's Hospital, Singapore
Lagos University Teaching Hospital, Nigeria
Lahore General Hospital, Pakistan
Liaquat National Hospital and Medical College, Pakistan
Mansoura University Hospitals, Egypt
Mater Dei Hospital, Sir Anthony Mamo Oncology Centre, Malta
Mayo Clinic, United States of America
Mbeya Zonal Referral Hospital, University of Dar es Salaam, Tanzania
Medical University of Pecs, Department of Paediatrics, Hungary
Menoufia University Hospital, Egypt
Ministry of Health Marmara University Pendik Research and Application Hospital, Turkey
MISR Cancer Centre, Egypt
National Cancer Institute, Brazil
National Cancer Institute, Sudan
National Hospital, Nigeria
Nnamdi Azikiwe University Teaching Hospital, Nigeria
Ola Doring Children's Hospital, Sierra Leone
Olabisi Onabanjo University Teaching Hospital, Nigeria
Ondokuz Mayıs Üniversitesi, Turkey
Pantai Jerudong Specialist Centre, Brunei
Pediatric Oncology Institute – GRAACC, Brazil
Policlinico Umberto I, Sapienza University of Rome, Italy
Post Graduate Institute of Medical Education and Research, Chandigarh, India
Prince Mohammed bin Nasser Hospital, Jazan, Saudi Arabia
Prince Sattam Bin Abdulaziz University, Saudi Arabia
Raparin Pediatric Teaching Hospital, Iraq
RIPAS Hospital, Brunei
Saadna Mohamed Abdenour, Algeria
Salmaniya Medical Complex, Bahrain
Shahid Baghaei Hospital, Iran
Sheba Medical Center/Tel HaShomer Hospital, Israel
St. George's Hospital, UK
Sultan Qaboos University Hospital, Muscat Sultanate of Oman
Tamale Teaching Hospital, Ghana
Tanta University Hospital, Egypt
The Hospital for Sick Children, Canada
The Indus Hospital, Pakistan
Tishreen University Hospital, Syria
Tobruk Medical Centre, Libya
Tripoli University Hospital, Libya
Unit of Paediatric and Adolescent Haematology and Oncology, 2nd Department of
Paediatrics, Aristotle University of Thessaloniki, University General Hospital AHEPA,
Greece

Universiti Kebangsaan Malaysia Medical Centre, Malaysia
University College Hospital (UCH), Nigeria
University Hospital Hamburg-Eppendorf, Germany
University of Abuja Teaching Hospital, Nigeria
University of Ilorin Teaching Hospital, Nigeria
University of Malaya Medical Centre, Malaysia
University of Texas Medical Branch, United States of America
University Teaching Hospital, Zambia
Usman Danfodiyo University Teaching Hospital, Nigeria
Vall d'Hebron University Hospital, Spain
Wingat Royal Hospital, Egypt
Yale New Haven Hospital, United States of America
Zagazig University Hospital, Egypt

Appendix S1: Global Children's NCDs Collaborative

Steering committee:

Soham Bandyopadhyay [UK], Noel Peter [UK] (Asia Lead), Kokila Lakhoo [UK], Simone de Campos Vieira Abib [Brazil] (South America Lead), Hafeez Abdelhafeez [Sudan] (Africa and Middle East Lead), Shaun Wilson [UK] (Australasia Lead), Max Pacht [UK] (Europe and North America Lead), Benjamin Martin [UK] (Europe Lead), Sonal Nagras [Australia] (Australasia Lead), and Mihir Sheth [India]

Operational committee:

Catherine Dominic [UK], Suraj Gandhi [UK], Divya Parwani [India], Rhea Raj [UAE], Diella Munezero [Burundi], Rohini Dutta [India], Nsimire Mulanga Roseline [DRC], Kellie McClafferty [UK], Armin Nazari [UK], Smrithi Sriram [UK], Sai Pillarisetti [UK], King-David Nweze [UK], Aishwarya Ashwinee [Grenada], Gul Kalra [India], Poorvaprabha Patil [India], Priyansh Nathani [India], Khushman Kaur Bhullar [India], Muhammed Elhadi [Libya], Maryam Khan [Pakistan], Nehal Rahim [Pakistan], Shweta Madhusudanan [UK], Joshua Erhabor [UK], Manasi Shirke [UK], Aishah Mughal [UK], Darica Au [UK], Mahan Salehi [UK], Sravani Royyuru [UK], Mohamed Ahmed [Egypt], Syeda Namayah Fatima Hussain [Pakistan], Daniel Robinson [UK], Anna Casey [UK], Mehdi Khan [UK], Alexandre Dukundane [Rwanda], Kwizera Festus [Rwanda], Vaishnavi Govind [Grenada], Rohan Pancharatnam [UK], Lorraine Ochieng [UK], Elliott H Taylor [UK], Hritik Nautiyal [UK], Marta de Andres Crespo [UK], Somy Charuvila [UK], and Alexandra Valetopoulou [UK]

Writing committee:

Soham Bandyopadhyay [UK], Amanpreet Brar [Canada], Hira Zuberi [Pakistan], Imane Ammouze [Morocco], Dhruva Ghosh [India], Nitin James Peters [India], Noel Peter [UK], and Kokila Lakhoo [UK]

Statistics committee:

Soham Bandyopadhyay [UK] and Mihir Sheth [India]

Local teams:

Abubakar Tafawa Balewa University Teaching Hospital, Nigeria

Kefas John Bwala

AM Umar

Abdurahaman Aremu

Dauda E. Suleiman

Tybat Aliyu

Aga Khan University Hospital, Pakistan

Ayesha Saleem

Muhammad Arshad

Kashaf Turk

Sadaf Altaf

Ahmadu Bello University Teaching Hospital, Nigeria

Oluseyi Oyebode Ogunsua

Tunde Talib Sholadoye

Musliu Adetola Tolani

Yakubu Alfa

Keffi Mubarak Musa

AIC Kijabe Hospital, Kenya

Eric Mwangi Irungu

Ken Muma

Sarah Muma

Mitchelle Obat

Ain Shams Hospitals "El-Demerdash", Egypt

Youssef Sameh Badran

Al-Basheer Hospital, Jordan

Abdulrahman Ghassan Qasem

Faris Ayasra

Reema Alnajjar

Al-Hussein University Hospital, Egypt

Mohamed Abdel-Maboud

Abdelrahman Bahaa

Ayat M. Saadeldin

Mohamed Adwi

Mahmoud Adly

Abdallah Elshenawy

Alder Hey Children Hospital, UK

Amer Harky

Leanne Gentle

Kirstie Wright

Jessica Luyt

Olivia White

Charlotte Smith

Nathan Thompson

Thomas Smith

Imogen Harrison

All India Institute of Medical Sciences (AIIMS), Bhubaneshwar, India

Santosh Kumar Mahalik

All India Institute of Medical Sciences (AIIMS), Rishikesh, India

Rajat Piplani

Enono Yhoshu

Manoj Gupta

Uttam Kumar Nath

Amit Sehrawat

Rajkumar K S

Vivek Singh

Augusta Victoria Hospital, Palestine

Sadi A. Abukhalaf

Bangladesh Shishu Hospital & Institute, Bangladesh

Ashrarur Rahman Mitul

Sabbir Karim

Nazmul Islam

Benghazi pediatric hospital, Libya

Sara Kader Alsaeiti

Fatma Saleh Benkhial

Mohammed Miftah Faraj Almihashhish

Eman Salem Muftah Burzeiza

Hend Mohammed Masoud

Mabroukah Saeid Alshamikh

Raja Mari Mohammed Nasef

Fatma Mohammed Masoud

Birmingham Children's Hospital, UK

William B Lo

Nyararai Togarepi

Elaine Carrolan

Benjamin Martin

Max Pachl

Benjamin J O'Sullivan

Borg El Arab University Hospital, Egypt

Mohamed Hassanin

Ahmed Saleh

Mahmoud Bassiony

Mostafa Qatora

Mohamed Bahaaeldin

Shady Fadel

Yasmine El Chazli

Centre Anti-Cancer, Batna, Algeria

Anfel Bouderbala

Kamel Hamizi

Safia Lorabi

Mehdi Anouar Zekkour

Rima Rahmoun

Boutheyna Drid

Salma Naje Abu Teir

Centre hospitalier universitaire de Batna, Algeria

Safia Lorabi

Mohamed Yazid Kadir

Yassine Zerizer

Nacer Khernane

Brahim Saada

Centre Hospitalo-Universitaire Ibn Sina de Rabat (CHIS), Morocco

Imane Ammouze

Yahya Elkaoune

Hajar Moujtahid

Ghita Chaoui

Hajar Benaouda

Meryem Gounni

Narjiss Aji

Laila Hessissen

Centro Hospitalar Universitário de São João, Portugal

Joana Mafalda Monteiro

Susana Nunes

Maria do Bom-Sucesso

Children's Hospital of Wisconsin, United States of America

Dave R. Lal

Brian T. Craig

Kerri Beckett

Chittagong Research Institute For Children Surgery, Bangladesh

Tahmina Banu

Md Afruzul Alam

Orindom Shing Pulock

Tasmiah Tahera Aziz

Christian Medical College & Hospital, Ludhiana, India

Vishal Michael

M Joseph John

William Bhatti

Bobby John

Swati Daniel

Jyoti Dhiman

Hunar Mahal

Atul Suroy

Clinic for Neurosurgery, Clinical Center of Serbia, Serbia

Rosanda Ilic

Danica Grujicic

Tijana Nastasovic

Igor Lazic

Mihailo Milicevic

Vladimir Bascarevic

Radovan Mijalcic

Vuk Scepanovic

Aleksandar Stanimirovic

Aleksandra Paunovic

Ivan Bogdanovic

Dayanand Medical College & Hospital Ludhiana, India

Shruti Kakkar

Shaina Kamboj

Suraj Singh

Dhaka Medical College Hospital, Bangladesh

Shahnoor Islam

AKM Amirul Morshed

A. K. M. Khairul Basher

Mehnaz Akter

S. M. Rezanur Rahman

Zannat Ara

Mohammed Tanvir Ahammed

Tania Akter

Kamrun Nahar

Fatema Sayed

Ashfaque Nabi

Md. Asif Iqbal

Md. Masud Rana

Md. Asaduzzaman

Md. Hasanuzzaman

Dr. Lutfi Kirdar Kartal Training and Research Hospital, Turkey

Kemal Tolga Saracoglu

Elif Akova

Evren Aydogmus

Bekir Can Kendirlioglu

Tufan Hicdonmez

Dubai Hospital, United Arab Emirates

Arshiya Adhnon

Asim Noor Rana

Hani Humad

Anjan Madasu

El Safa Hospital, Egypt

Ahmed Y Azzam

Mohammed A Azab

El Sheikh Zayed Specialized Hospital, Egypt

Sherief Ghozy

Alzhraa Salah Abbas

El-Salam Hospital, Egypt

Monica Dobs

Mohamed Atef Mohamed Ghamry

Mohammed Alhendy

Faculty of Medicine, University of Porto, Portugal

Joana Monteiro

Federal Medical Center, Abeokuta, Nigeria

Olanrewaju Moses

Federal Medical Center, Lokoja, Nigeria

Ibiyeye Taiye Taibat

Taiwo Jones

Kalu Ukoha

Olagundoye Goke

Okorie Ikechukwu

Federal Teaching Hospital Ido-Ekiti, Nigeria

Abiodun Idowu Okunlola

Frere Hospital, South Africa

Milind Chitnis

Helga Nauhaus

Danelle Erwee

Gloucestershire Hospitals NHS Foundation Trust, United Kingdom

Robyn Brown

Agata Chylinska

Robin Simpson

Prasanna Gomes

Noel Peter

GPACI - Grupo de Pesquisa e Assistência ao Câncer Infantil, Brazil

Marco Aurelio Ciriaco Padilha

Elvercio Pereira de Oliveira Junior

Lucas Garschagen de Carvalho

Fabiola Leonelli Diz

Helwan University Hospital, Egypt

Mohamed El Kassas

Usama Eldaly

Ahmed Tawheed

Mohamed Abdelwahab

Hôpital des Spécialités ONO, Morocco

Oudrhiri Mohammed Yassaad

Bechri Hajar

El Ouahabi Abdessamad

Arkha Yasser

Hessissen Laila

Ibn-Al-Atheer Teaching Hospital, Mosul, Iraq

Farah Sameer Yahya (Department of Pediatrics, College of Medicine, University of Mosul, Mosul, Iraq)

Yasir Al-Agele

Indira Gandhi Institute of Medical Sciences (IGIMS), India

Sandip Kumar Rahul

Vijayendra Kumar

Digamber Chaubey

Instituto Nacional de Enfermedades Neoplásicas, Peru

Maria Teresa Peña Gallardo

Jacqueline Elizabeth Montoya Vásquez

Juan Luis García León

Sebastián Shu Yip

Ipswich Hospital NHS Trust, UK

Georgios Karagiannidis

Istanbul University, Turkey

Rejin Kebudi

Sema Bay Buyukkapu

Jawaharlal Institute of Postgraduate Medical Education and Research, India

Krishna Kumar Govindarajan

Kumaravel Sambandan

Smita Kayal

Gunaseelan Karunanithi

Bikash Kumar Naredi

Bibekanand Jindal

John Radcliffe Hospital, United Kingdom

Mariam Lami

Matthew H V Byrne

Duha Jasim

Harmit Ghataura

Soham Bandyopadhyay

Kokila Lakhoo

Johns Hopkins Hospital Bloomberg Children's Hospital, United States of America

Eric W Etchill

Daniel Rhee

Stacy Cooper

Kevin Crow

Morgan Drucker

Megan Murphy

Benjamin Shou

Alan Siegel

Kanuni Sultan Süleyman Research and Training Hospital, Turkey

Yasin Kara

Gül Nihal Özdemir

Kasr Al Ainy Hospital, Egypt

Mahmoud Elfiky

Ehab El Refaee

Khoula Hospital, Oman

John George Massoud

King Abdullah University Hospital, Jordan

Ayah Bassam Ibrahim

Ruaa Bassam Ibrahim

Faris Abu Za'nouneh

Ranya M. Baddourah

Toqa Fahmawee

Ayah Al_Shraideh

King Fahd Central Hospital, Saudi Arabia

Ghazwani Salman

Ehab Alameer (Jazan University)

Al-Mudeer Ali

Ghazwani Yahia

Khozairi Waleed

King George's Medical University, India

Ahmad Ozair

Ankur Bajaj

Bal Krishna Ojha

Kaushal Kishor Singh

Atique Anwar

Vinay Suresh

King Hussein Cancer Center, Jordan

Mohamad K. Abou Chaar

Iyad Sultan

Khalil Ghandour

Shaima' Al-Dabaibeh

Ammar Al-Basiti

Hazim Ababneh

Omaima El-Qurneh

King Salman Armed Forces Hospital, Saudi Arabia

Yousef Alalawi

Ahmad Al Ayed

Ehab Hanafy

Naif Al Bolowi

KK Women's and Children's Hospital, Singapore

Amos HP Loh

Anette S Jacobsen

Heidi Barola

Aubrey L Pagaduan

Jingdan Fan

Lagos University Teaching Hospital, Nigeria

Olumide Abiodun Elebute

Adesoji O. Ademuyiwa

Christopher O. Bode

Justina O. Seyi-Olajide

Oluwaseun Ladipo-Ajayi

Felix M. Alakaloko

George C. Ihediwa

Kareem O. Musa

Edamisan O. Temiye

Olufemi Oni

Adeseye M. Akinsete

Lahore General Hospital, Pakistan

Janita Zarrish

Ramsha Saleem

Soha Zahid

Atiqa Amirali

Ahsan Nadeem

Sameer Saleem Tebha

Zonaira Qayyum

Sana Tahir

Anneqa Tahir

Rabbey Raza Khan

Ayesha Mehmood

Iqra Effendi

Liaquat National Hospital and Medical College, Pakistan

Muhammad Arshad

Taimur Iftikhar Qureshi

Pooja Kumari

Mansoura University Hospitals, Egypt

Mohamed Bonna

Khaled Mamdouh

Mohamed Atef

Mohamed Faried

Mater Dei Hospital, Sir Anthony Mamo Oncology Centre, Malta

Victor Calvagna

Nathalie Galea

Ariana Axiaq

Mayo Clinic, United States of America

Matthew R Schuelke

Jake A. Kloeber

Robert L. Owen

Alexander S. Roth

Catherine Yang

J. Hudson Barnett

Lucien P. Jay

Kirk David Wyatt

Paul J. Galardy

Mbeya Zonal Referral Hospital, University of Dar es Salaam, Tanzania

Bernard Mbwele

Irene Nguma

Moshi Moshi Shabani

Amani Twaha

Bilal Matola

Medical University of Pecs, Department of Paediatrics, Hungary

Agnes Vojcek

Menoufia University Hospital, Egypt

Mahmoud Maher Abdelnaby Alrahawy

Seham M Ragab

Abdallah R Allam
Eman Ibrahim Hager
Abdelrahman Azzam
Ammar Ayman
**Ministry of Health Marmara University Pendik Research and Application Hospital,
Turkey**
Kıvılcım Karadeniz Cerit
Adnan Dağçınar
Tümay Umuroğlu
Ayten Saraçoğlu
Mustafa Sakar
Can Kıvrak
Gül Çakmak
MISR Cancer Centre, Egypt
Ibrahim Sallam
Gamal Amira
Mohamed Sherief
Ahmed Sherif
National Cancer Institute, Brazil
Simone de Oliveira Coelho
Arisa Ikeda
Licia Portela
Marianne Monteiro Garrigo
Ricardo Vianna de Carvalho
Fernanda Lobo
Sima Ester Ferman
Fernanda Ferreira da Silva Lima
National Cancer Institute, Sudan
Moawia Mohammed Ali Elhassan
Nada Osman Yousif Elhaj
Hytham K. S. Hamid
National Hospital, Nigeria
Emmanuel A. Ameh
Vincent E. Nwatah
Adewumi B. Oyesakin
Nnamdi Azikiwe University Teaching Hospital, Nigeria
Andrew Nwankwo Osuigwe
Okechukwu Hyginus Ekwunife
Chisom Adaobi Nri-Ezedi
Eric Okechukwu Umeh
Ola Daring Children's Hospital, Sierra Leone
Nellie Bell
Olabisi Onabanjo University Teaching Hospital, Nigeria
Ibukunolu Olufemi Ogundele
Abiodun Folashade Adekanmbi
Olubunmi Motunrayo Fatungase
Olubunmi Obafemi Obadaini
Ondokuz Mayıs Üniversitesi, Turkey
Sarah Al-Furais
Humaida Hemlae

Sreylis Nay

Pantai Jerudong Specialist Centre, Brunei

John Mathew

R M Jeffri Ismail

Pediatric Oncology Institute – GRAACC, Brazil

Simone de Campos Vieira Abib

Fabianne Altruda de Moraes Costa Carlesse

Mayara Caroline Amorim Fanelli

Fernanda Kelly Marques de Souza

Policlinico Umberto I, Sapienza University of Rome, Italy

Pierfrancesco Lapolla

Andrea Mingoli

Denis Cozzi

Anna Maria Testi

Paolo Musiu

Paolo Sapienza

Gioia Brachini

Martina Zambon

Simona Meneghini

Pierfranco Cicerchia

Bruno Cirillo

Post Graduate Institute of Medical Education and Research, Chandigarh, India

Manjul Tripathi

Nitin James Peters

Sandeep Mohindra

Vishal Kumar

Ninad R Patil

Richa Jain

Renu Madan

Madhivanan Karthigeyan

Pravin Salunke

Prince Mohammed bin Nasser Hospital, Jazan, Saudi Arabia

Ghazwani Salman

Prince Sattam Bin Abdulaziz University, Saudi Arabia

Gopal Nambi

Raparin Pediatric Teaching Hospital, Iraq

Abdulrahman Omar Taha

RIPAS Hospital, Brunei

Janice Hui Ling Wong

Norehan Johari

Anas Shikha

Win Sabai Phyu Han

Zahidah Ahmad

Yen Yan Lim

Roserahayu Idros

Noorainun Mohd Yusof

David Nelson Jaisingh

Saadna Mohamed Abdenour, Algeria

Aouabed Nesrine

Bouaoud Souad

Mebarki Malika
Bioud Belkacem
Salmaniya Medical Complex, Bahrain
Fayza Haider
Fatema Naser Al Fayeze
Shahid Baghaei Hospital, Iran
Fakher Rahim
Sheba Medical Center/Tel HaShomer Hospital
Elana Kleinman
Taylor Ibelli
Emily Hamilton
Rochelle Fayngor
Tzvi Najman
Gideon Karplus
Etai Adam
Daniella Melamed
Cecilia Paasche
St. George's Hospital, UK
Amir Labib
Sultan Qaboos University Hospital, Muscat Sultanate of Oman
Farman Ali Laghari
Dhruva Ghosh
Zainab Al Balushi
Abdulkhaleq Awadh Salim Al-Rawas
Ali Al Sharqi
Ammar Saif Al Shabibi
Ismail Al Bulushi
Muna Alshahri
Abdulrahman AlMirza
Ola Al Hamadani
Jawaher Al Sharqi
Anisa Al Shamsi
Bashar Dawud
Sareya Al Sibai
Tamale Teaching Hospital, Ghana
Alhassan Abdul-Mumin
Halwani Yaninga Fuseini
Peter Gyamfi Kwarteng
Abubakari Bawa Abdulai
Sheba Mary Pognaa Kunfah
Gilbert B. Bonsaana
Stephanie Ajinkpang
Edmund M. Der
Francis A. Abantanga
Mary Joan Kpiniong
Kingsley Aseye Hattor
Kingsley Appiah Bimpong
Tanta University Hospital, Egypt
Mohamed Elbahnasawy
Sherief Abdelsalam

Ahmed Samir

The Hospital for Sick Children, Canada

Reto M. Baertschiger

Amanpreet Brar

Andreea C. Matei

Augusto Zani

The Indus Hospital, Pakistan

Lubna Samad

Hira Khalid Zuberi

Kishwer Nadeem

Naema Khayyam

Fatima Ambreen Imran

Nida Zia

Sadia Muhammad

Muhammad Rafie Raza

Muhammad Rahil Khan

Tishreen University Hospital, Syria

Alaa Hamdan

Ammar Omran

Ahmed Moussa

Bardisan Gawrieh

Hassan Salloum

Alaa Ahmed

Abdeljawad Mazloun

Ali Abodest

Nisreen Ali

Munawar Hraib

Victor Khoury

Abdulrahman Almjersah

Mohammad Ali Deeb

Mohammad Ahmad Almahmod Alkhalil

Akram Ahmed

Waseem Shater

Ali Farid Alelayan

Alaa Guzman

Tobruk Medical Centre, Libya

Ahmad Bouhuwaish

Alqasim Abdulkarim

Tripoli University Hospital, Libya

Eman Abdulwahed

Marwa Biala

Reem Ghamgh

Amani Alamre

Marwa Shelft

Asmaa A. M. Albanna

Hoda Tawel

Unit of Paediatric and Adolescent Haematology and Oncology, 2nd Department of Paediatrics, Aristotle University of Thessaloniki, University General Hospital AHEPA, Greece

Emmanuel Hatzipantelis

Athanasios Tragiannidis

Eleni Tsotridou

Assimina Galli-Tsinopoulou

Universiti Kebangsaan Malaysia Medical Centre, Malaysia

Dayang Anita Abdul Aziz

Zarina Abdul Latiff

Hamidah Alias

C-Khai Loh

Doris Lau

Azrina Syarizad Khutubul Zaman

University College Hospital (UCH), Nigeria

Taiwo Akeem Lawal

Kelvin Ifeanyichukwu Egbuchulem

Olakayode Olaolu Ogundoyin

Isaac Dare Olulana

Biobele J. Brown

Oluwasegun Joshua Afolaranmi

AbdulBasit Fehintola

University Hospital Hamburg-Eppendorf, Germany

Annika Heuer

Christine Nitschke

Michael Boettcher

Matthias Priemel

Lennart Viezens

Martin Stangenberg

Marc Dreimann

Alonja Reiter

Jasmin Meyer

Leon Köpke

Karl-Heinz Frosch

University of Abuja Teaching Hospital, Nigeria

Samson Olori

Uduak Offiong

Philip Mari Mshelbwala

Fashie Andrew Patrick

Aminu Muhammed Umar

Otene ThankGod N.

University of Ilorin Teaching Hospital, Nigeria

Abdulrasheed A Nasir

Kazeem O. O. Ibrahim

Dupe S. Ademola-Popoola

Olayinka T. Sayomi

Alege Abdurrzzaq

Ademola A. Adeyeye

Khadijah O. Omokanye

Lukman O Abdur-Rahman

Olubisi Olutosin Bamidele

Shakirullah AbdulAzeez

Aminat Akinoso

Michael O. Adegboye

University of Malaya Medical Centre, Malaysia

Shireen Anne Nah

Yuki Julius Ng

Syukri Ahmad Zubaidi

University of Texas Medical Branch, United States of America

Murad Almasri

Sara Ali

Rasaq Olaosebikan

Akila Muthukumar

University Teaching Hospital, Zambia

Patricia Shinondo

Amon Ngongola

Bruce Bvulani

Azad Patel

Usman Danfodiyo University Teaching Hospital, Nigeria

Abdullahi Nuhu-Koko

Baba Jibrin

Ajiboye L. Olalekan

Christopher S. Lukong

Ezekiel I. Ajayi

Vall d'Hebron University Hospital, Spain

Gabriela Guillén

Sergio López

José Andrés Molino

Pablo Velasco

Wingat Royal Hospital, Egypt

Omar Elmandouh

Omar Hamam

Rim Elmandouh

Yale New Haven Hospital, United States of America

Nensi Melissa Ruzgar

Rachel Levinson

Shashwat Kala

Sarah Ullrich

Emily Christison-Lagay

Zagazig University Hospital, Egypt

Aya Sabry Mortada

Mahmoud Ahmed Ebada

Eman Seif Alnaser Solimam

Khaled Abualkher

Amr Mohammed Elsayed Yousf

Mohamed Mohamed Holail

Reem Mohamed Almowafy

National/Regional Leads:

Algeria: Salah Eddine Oussama Kacimi

Bahrain: Fayza Haider

Bangladesh: Tahmina Banu, Ashrarur Rahman Mitul

Brazil: Simone de Campos Vieira Abib

Brunei: Janice Hui Ling Wong

Canada: Reto Baertschiger
Egypt: Essam Elhalaby, Muath Alser, Mahmoud M. Saad
France: Luca Pio
Germany: Guido Seitz, Judith Lindbert
Ghana: Francis Abantanga
Greece: Georgios Tsoulfas, Asimina Galli-Tsinopoulou
Hungary: Agnes Vojcek
India: Dhruva Ghosh, Nitin James Peter, Ankur Bajaj, Vrisha Madhuri, Ravi Kishore
Iran: Maryam Ghavami Adel
Iraq: Abdulrahman Omar Taha
Italy: Calogero Virgone, Francesco Pata, Gaetano Gallo
Jordan: Mohammad K. Abou Chaar, Faris Ayasra
Kenya: Eric Mwangi Irungu
Libya: Muhammed Elhadi
Malaysia: Shireen Anne Nah, Dayang Anita Abdul Aziz
Malta: Victor Calvagna
Morocco: Outani Oumaima, Zineb Bentounsi, Hajar Moujtahid
Nigeria: Adesoji Ademuyiwa
Oman: Dhruva Nath Ghosh
Pakistan: Muhammad Arshad, Lubna Samad
Peru: Lily Saldana
Portugal: Jan Godzinsky
Saudi Arabia: Abdelbasit Ali, Ehab Alameer
Serbia: Dragana Janic
Sierra Leone: Mohamed Bella Jalloh, Nellie Bell
Singapore: Annette Jacobsen, Chan Hon Chui
South Africa: Milind Chitnis
Spain: Israel Fernandez Pineda, Lucas Krauel, Maricarmen Olivos
Sudan: Waha Rahama, Hazim Elfatih
Switzerland: Raphael N. Vuille-dit-Bille
Syria: Alaa Hamdan
Turkey: Arda Isik
United Arab Emirates: Asim Noor Rana
United Kingdom: Kokila Lakhoo, Kate Cross, Max Pacht
United States of America: Andrea Hayes-Jordan, Roshni Dasgupta
Zambia: Patricia Shinondo, Amon Ngongola
Middle-East and North Africa: Mohamedraed Elshami


STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

| | Item No | Recommendation | Page No |
|------------------------------|----------------|--|----------------|
| Title and abstract | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract | 1 |
| | | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | 2 |
| Introduction | | | |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 3 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | 4 |
| Methods | | | |
| Study design | 4 | Present key elements of study design early in the paper | 4 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 4 |
| Participants | 6 | (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed | 4 |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 4-5 |
| Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 4-5 |
| Bias | 9 | Describe any efforts to address potential sources of bias | 4 |
| Study size | 10 | Explain how the study size was arrived at | 4-5 |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 4-5 |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses | 5 |
| Results | | | |
| Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram | 6 |
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount) | 7 |
| Outcome data | 15* | Report numbers of outcome events or summary measures over time | 7-15 |

| | | | |
|--------------------------|----|---|-------|
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | 7-9 |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | 9-15 |
| Discussion | | | |
| Key results | 18 | Summarise key results with reference to study objectives | 15 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 17 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 15-17 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | 16 |
| Other information | | | |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 18 |

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.



Countries participating in this study shaded in blue

| | |
|------------|--------------------|
| Algeria | – 55 participants |
| Bahrain | – 19 participants |
| Bangladesh | – 58 participants |
| Brazil | – 139 participants |
| Brunei | – 16 participants |
| Canada | – 43 participants |
| Egypt | – 66 participants |
| Germany | – 3 participants |
| Ghana | – 8 participants |
| Greece | – 23 participants |
| Hungary | – 20 participants |
| India | – 195 participants |
| Iran | – 1 participant |
| Iraq | – 10 participants |
| Israel | – 3 participants |
| Italy | – 29 participants |
| Jordan | – 262 participants |
| Kenya | – 9 participants |
| Libya | – 34 participants |
| Malaysia | – 40 participants |
| Malta | – 16 participants |
| Morocco | – 98 participants |
| Nigeria | – 126 participants |
| Oman | – 49 participants |
| Pakistan | – 132 participants |
| Peru | – 5 participants |

Portugal – 12 participants
Saudi Arabia – 15 participants
Serbia – 24 participants
Sierra Leone – 6 participants
Singapore – 38 participants
South Africa – 71 participants
Spain – 106 participants
Sudan – 11 participants
Syria – 19 participants
Tanzania – 4 participants
Turkey – 63 participants
United Arab Emirates – 24 participants
United Kingdom – 152 participants
United States of America – 100 participants
Zambia – 14 participants

Appendix S4 – Health system framework factors affected by the COVID-19 pandemic by World Bank income group

| Number of patients affected by treatment type and World Bank income group | Changes to treatment due to the COVID-19 pandemic |
|--|---|
| Low-income countries Chemotherapy (n = 4) Radiotherapy (n = 0) Immunotherapy (n = 0) Surgery (n = 1) | <ul style="list-style-type: none"> - Cancelled (n = 2) - Delayed (n = 2) - Shorter duration of treatment (n = 1) - Change in route of administration of chemotherapy agent (n = 1) NA NA <ul style="list-style-type: none"> - Operation performed in an alternative hospital (n = 1) |
| Lower-middle income countries Chemotherapy (n = 141) Radiotherapy (n = 32) Immunotherapy (n = 1) Surgery (n = 63) | <ul style="list-style-type: none"> - Cancelled (n = 8) - Delayed (n = 93) - Reduction in dose (n = 7) - Increase in dose (n = 4) - Reduction in the number of cycles (n = 7) - Increase in the number of cycles (n = 8) - Shorter duration of treatment (n = 5) - Longer duration of treatment (n = 19) - Change in choice of agent (n = 21) - Change in route of administration of chemotherapy agent (n = 7) - Change to/addition of an alternative anti-cancer treatment modality (n = 5) <ul style="list-style-type: none"> - Cancelled (n = 3) - Delayed (n = 25) - Change in modality (n = 3) - Change to/addition of an alternative anti-cancer treatment modality (n = 2) <ul style="list-style-type: none"> - Delayed (n = 1) <ul style="list-style-type: none"> - No longer offered (n = 1) - Abandoned (n = 2) - Delayed (n = 45) - Change in choice of operation (n = 8) - Operation performed in an alternative hospital (n = 6) - Underwent neoadjuvant therapy where this would not typically have been indicated (n = 2) - No neoadjuvant therapy given, where this would typically have been indicated (n = 2) - Underwent a longer or more intensive course of neoadjuvant therapy that would have typically been indicated (n = 6) - Underwent a shorter or less intensive course of neoadjuvant therapy that would have typically been indicated (n = 1) - No adjuvant therapy, where this would typically have been indicated (n = 1) - Changed to active palliative care (n = 2) |
| Upper-middle income countries Chemotherapy (n = 44) | <ul style="list-style-type: none"> - Cancelled (n = 8) - Delayed (n = 25) - Reduction in dose (n = 3) - Change in choice of agent (n = 9) |



| | | |
|--------------------------------------|-----------------------|--|
| | | - Change to/addition of an alternative anti-cancer treatment modality (n = 1) |
| | Radiotherapy (n = 0) | NA |
| | Immunotherapy (n = 1) | - Delayed (n = 1) |
| | Surgery (n = 20) | - Delayed (n = 17) - Change in choice of operation (n = 1) - Operation performed in an alternative hospital (n = 2) |
| High income countries | Chemotherapy (n = 23) | - Delayed (n = 17) - Reduction in dose (n = 2) - Increase in the number of cycles (n = 1) - Shorter duration of treatment (n = 1) - Change in choice of agent (n = 1) - Change to/addition of an alternative anti-cancer treatment modality (n = 2) |
| | Radiotherapy (n = 10) | - Delayed (n = 9) - Change in modality (n = 1) |
| | Immunotherapy (n = 3) | - Delayed (n = 3) |
| | Surgery (n = 14) | - Delayed (n = 12) - Change in choice of operation (n = 1) - Operation performed in an alternative hospital (n = 1) - Underwent a longer or more intensive course of neoadjuvant therapy that would have typically been indicated (n = 1) |
| | | Reasons for changes to treatment due to the COVID-19 pandemic |
| Low-income countries | Chemotherapy | Decision making (n = 1) - Change in treatment as per local MDT / hospital policy (n = 1) Infrastructure (n = 2) - Lockdown/Travel restrictions prevent access to treatment (n = 2) - Lack of hospital inpatient beds (infrastructure) (n = 2) Workforce (n = 1) - Insufficient staff due to redeployment/restructuring (n = 1) |
| | Radiotherapy | NA |
| | Immunotherapy | NA |
| | Surgery | Service delivery (n = 1) - Transfer to a different institution for treatment (n = 1) |
| | | |
| Lower-middle income countries | Chemotherapy | Decision making (n = 55) - Change in treatment as per local MDT / hospital policy (n = 24) - Change in treatment as per regional policy (n = 1) - Change in treatment as per national policy (n = 9) - Change in treatment plan by lead clinician (n = 28) Infrastructure (n = 74) - Lockdown/Travel restrictions prevent access to treatment (n = 66) - Lack of hospital inpatient beds (infrastructure) (n = 13) - Lack of hospital intensive care beds (n = 2) - Lack of outpatient facilities for support post-discharge (n = 4) - Lack of blood products (n = 3) - Lack of personal protective equipment (n = 6) - Lack of drugs (n = 9) Workforce (n = 18) - Insufficient staff due to redeployment/restructuring (n = 16) - Insufficient staff due to sickness (n = 8) Service delivery (n = 14) - No treatment available due to restructuring of services (n = 5) |

| | |
|---------------|--|
| | <ul style="list-style-type: none"> - Transfer to a different institution for treatment (n = 9) <p>Financing (n = 11)</p> <ul style="list-style-type: none"> - Inability to pay for treatment (n = 7) - Loss of employment by caregiver (n = 5) <p>Patient factors (n = 38)</p> <ul style="list-style-type: none"> - Patient/patient's family chooses to avoid treatment during the pandemic (n = 33) - Treatment not possible as caregiver infected with SARS-CoV-2 and under mandatory isolation (n = 3) - Treatment not possible as patient infected with SARS-CoV-2 and under mandatory isolation (n = 2) <p>Other factors (n = 7)</p> |
| Radiotherapy | <p>Decision making (n = 10)</p> <ul style="list-style-type: none"> - Change in treatment as per local MDT / hospital policy (n = 4) - Change in treatment as per national policy (n = 2) - Change in treatment plan by lead clinician (n = 4) <p>Infrastructure (n = 20)</p> <ul style="list-style-type: none"> - Lockdown/Travel restrictions prevent access to treatment (n = 14) - Lack of hospital inpatient beds (infrastructure) (n = 4) - Lack of outpatient facilities for support post-discharge (n = 2) - Lack of personal protective equipment (n = 1) - Lack of equipment (n = 1) <p>Workforce (n = 9)</p> <ul style="list-style-type: none"> - Insufficient staff due to redeployment/restructuring (n = 9) - Insufficient staff due to sickness (n = 6) <p>Service delivery (n = 10)</p> <ul style="list-style-type: none"> - No treatment available due to restructuring of services (n = 8) - Transfer to a different institution for treatment (n = 2) <p>Financing (n = 6)</p> <ul style="list-style-type: none"> - Inability to pay for treatment (n = 5) - Loss of employment by caregiver (n = 1) <p>Patient factors (n = 8)</p> <ul style="list-style-type: none"> - Patient/patient's family chooses to avoid treatment during the pandemic (n = 6) - Treatment not possible as patient infected with SARS-CoV-2 and under mandatory isolation (n = 2) <p>Other factors (n = 1)</p> |
| Immunotherapy | <p>Infrastructure (n = 1)</p> <ul style="list-style-type: none"> - Lack of outpatient facilities for support post-discharge (n = 1) |
| Surgery | <p>Decision making (n = 19)</p> <ul style="list-style-type: none"> - Change in treatment as per local MDT / hospital policy (n = 12) - Change in treatment as per regional policy (n = 1) - Change in treatment plan by lead clinician (n = 7) <p>Infrastructure (n = 37)</p> <ul style="list-style-type: none"> - Lockdown/Travel restrictions prevent access to treatment (n = 27) - Lack of hospital inpatient beds (infrastructure) (n = 9) - Lack of hospital intensive care beds (n = 13) - Lack of outpatient facilities for support post-discharge (n = 1) - Lack of blood products (n = 1) - Lack of personal protective equipment (n = 3) - Lack of equipment (n = 2) - Lack of drugs (n = 1) <p>Workforce (n = 8)</p> <ul style="list-style-type: none"> - Insufficient staff due to redeployment/restructuring (n = 8) - Insufficient staff due to sickness (n = 6) <p>Service delivery (n = 15)</p> |

| | | |
|--------------------------------------|---------------|--|
| | | <ul style="list-style-type: none"> - No treatment available due to restructuring of services (n = 9) - Transfer to a different institution for treatment (n = 7) Financing (n = 3) <ul style="list-style-type: none"> - Inability to pay for treatment (n = 2) - Loss of employment by caregiver (n = 1) Patient factors (n = 10) <ul style="list-style-type: none"> - Patient/patient's family chooses to avoid treatment during the pandemic (n = 9) - Treatment not possible as caregiver infected with SARS-CoV-2 and under mandatory isolation (n = 1) Other factors (n = 7) |
| Upper-middle income countries | Chemotherapy | Decision making (n = 36) <ul style="list-style-type: none"> - Change in treatment as per local MDT / hospital policy (n = 31) - Change in treatment as per regional policy (n = 2) - Change in treatment as per national policy (n = 1) - Change in treatment plan by lead clinician (n = 7) Infrastructure (n = 3) <ul style="list-style-type: none"> - Lockdown/Travel restrictions prevent access to treatment (n = 2) - Lack of hospital inpatient beds (infrastructure) (n = 1) Service delivery (n = 3) <ul style="list-style-type: none"> - No treatment available due to restructuring of services (n = 2) - Transfer to a different institution for treatment (n = 1) Patient factors (n = 2) <ul style="list-style-type: none"> - Patient/patient's family chooses to avoid treatment during the pandemic (n = 2) |
| | Radiotherapy | NA |
| | Immunotherapy | Data not available (n = 1) |
| | Surgery | Decision making (n = 13) <ul style="list-style-type: none"> - Change in treatment as per local MDT / hospital policy (n = 11) - Change in treatment plan by lead clinician (n = 2) Infrastructure (n = 15) <ul style="list-style-type: none"> - Lockdown/Travel restrictions prevent access to treatment (n = 15) Workforce (n = 3) <ul style="list-style-type: none"> - Insufficient staff due to redeployment/restructuring (n = 3) Service delivery (n = 3) <ul style="list-style-type: none"> - No treatment available due to restructuring of services (n = 1) - Transfer to a different institution for treatment (n = 2) |
| High income countries | Chemotherapy | Decision making (n = 12) <ul style="list-style-type: none"> - Change in treatment as per local MDT / hospital policy (n = 4) - Change in treatment as per regional policy (n = 1) - Change in treatment plan by lead clinician (n = 7) Infrastructure (n = 5) <ul style="list-style-type: none"> - Lockdown/Travel restrictions prevent access to treatment (n = 1) - Lack of hospital inpatient beds (infrastructure) (n = 3) - Lack of outpatient facilities for support post-discharge (n = 1) - Lack of drugs (n = 1) Workforce (n = 1) <ul style="list-style-type: none"> - Insufficient staff due to sickness (n = 1) Service delivery (n = 2) <ul style="list-style-type: none"> - Transfer to a different institution for treatment (n = 2) Patient factors (n = 8) <ul style="list-style-type: none"> - Patient/patient's family chooses to avoid treatment during the pandemic (n = 1) - Treatment not possible as caregiver infected with SARS-CoV-2 and under mandatory isolation (n = 1) |


| | |
|---------------|---|
| | <ul style="list-style-type: none"> - Treatment not possible as patient infected with SARS-CoV-2 and under mandatory isolation (n = 3) - Treatment not possible as patient and caregiver under mandatory isolation, but not infected with SARS-CoV-2 (n = 3) <p>Other factors (n = 2)</p> |
| Radiotherapy | <p>Decision making (n = 5)</p> <ul style="list-style-type: none"> - Change in treatment as per regional policy (n = 2) - Change in treatment plan by lead clinician (n = 3) <p>Infrastructure (n = 2)</p> <ul style="list-style-type: none"> - Lockdown/Travel restrictions prevent access to treatment (n = 2) <p>Service delivery (n = 3)</p> <ul style="list-style-type: none"> - No treatment available due to restructuring of services (n = 1) - Transfer to a different institution for treatment (n = 2) <p>Patient factors (n = 2)</p> <ul style="list-style-type: none"> - Patient/patient's family chooses to avoid treatment during the pandemic (n = 1) - Treatment not possible as patient infected with SARS-CoV-2 and under mandatory isolation (n = 1) <p>Other factors (n = 1)</p> |
| Immunotherapy | <p>Decision making (n = 2)</p> <ul style="list-style-type: none"> - Change in treatment as per local MDT / hospital policy (n = 1) - Change in treatment plan by lead clinician (n = 1) <p>Patient factors (n = 1)</p> <ul style="list-style-type: none"> - Patient/patient's family chooses to avoid treatment during the pandemic (n = 1) |
| Surgery | <p>Decision making (n = 7)</p> <ul style="list-style-type: none"> - Change in treatment as per local MDT / hospital policy (n = 3) - Change in treatment as per regional policy (n = 2) - Change in treatment as per national policy (n = 1) - Change in treatment plan by lead clinician (n = 1) <p>Infrastructure (n = 4)</p> <ul style="list-style-type: none"> - Lockdown/Travel restrictions prevent access to treatment (n = 3) - Lack of hospital intensive care beds (n = 1) <p>Service delivery (n = 4)</p> <ul style="list-style-type: none"> - Transfer to a different institution for treatment (n = 4) <p>Financing (n = 2)</p> <ul style="list-style-type: none"> - Inability to pay for treatment (n = 2) <p>Patient factors (n = 2)</p> <ul style="list-style-type: none"> - Patient/patient's family chooses to avoid treatment during the pandemic (n = 1) - Treatment not possible as caregiver infected with SARS-CoV-2 and under mandatory isolation (n = 1) |

Appendix S5

Low-and-Middle
Income CountriesHigh Income
Countries

Venn diagrams of treatments planned in initial multi-disciplinary team meeting for patients who were switched to palliative care

Appendix S6



Stacked and clustered bar chart of 30-day complications after starting various anti-cancer therapies

Author Reflexivity Statement

How does this study address local research and policy priorities?

The study was conceived together with local researchers in LMICs following concerns regarding the care of paediatric cancer patients in HICs and LMICs. Therefore, this study was designed in a way to best address the questions and priorities of researchers, clinicians, and policy makers in both HICs and LMICs.

How were local researchers involved in study design?

Local researchers were involved in the conception, design, conduct, interpretation, and writing of this manuscript. Therefore, they have been involved and led every aspect of this study.

How has funding been used to support the local research team(s)?

All the funding has gone to support local research teams in conducting this study. None of this funding has been used by HIC collaborators. Funding has also been used to support and develop a research capacity building course.

How are research staff who conducted data collection acknowledged?

All individuals who were involved in collecting data are listed as collaborative authors as per our study protocol.

How have members of the research partnership been provided with access to study data?

All individuals have been provided with access to data collected from their centre. We have also provided country-level data to all centres within a country where requested.

How were data used to develop analytical skills within the partnership?

A research capacity building course was utilised which allowed all members to develop statistical skills

How have research partners collaborated in interpreting study data?

Conversations have been held with various research partners to establish their interpretation of the results, and these have been incorporated into the study manuscript.

How were research partners supported to develop writing skills?

The research team writing this statement is composed of authors from HICs and LMICs of various levels of academic seniority.

How will research products be shared to address local needs?

This publication will be published as open access. We have developed a post-publication dissemination plan to distribute recommendations across a wide constituency. This will include engagement with research leaders in global health, cancer, and paediatrics, and with journalists based in HICs and LMICs.

How is the leadership, contribution and ownership of this work by LMIC researchers recognised within the authorship?

They are all listed as authors and their specific roles have been outlined.

How have early career researchers across the partnership been included within the authorship team?

They are all listed as authors and their specific roles have been outlined. Early career researchers have been involved in all aspects of this study.

How has gender balance been addressed within the authorship?

The chief investigator of this study is a female originally from South Africa (Professor Kokila Lakhoo). We have females from both LMICs and HICs at all levels of seniority present in our authorship.

How has the project contributed to training of LMIC researchers?

We have used a research capacity building course to train LMIC researchers in designing and conducting their own studies in the future.

How has the project contributed to improvements in local infrastructure?

The results from this project will be used by local researchers to quality improvement projects and get buy-in for improvements in local infrastructure

What safeguarding procedures were used to protect local study participants and researchers?

There was no primary data collection as part of this project, therefore this question is not directly applicable. We have specifically considered the issue of safeguarding within the study protocol.